Interim Condensed Consolidated Financial Statements of

### **GOLDEN LEAF HOLDINGS LTD.**

For the three and nine months ended September 30, 2018 (Unaudited)

Notes to the Interim Condensed Consolidated Financial Statements (Expressed in U.S. dollars, unless otherwise stated) For the three and nine months ended September 30, 2018 and 2017

Notice of No Auditor Review of Interim Condensed Financial Statementsi
Interim Condensed Consolidated Statement of Financial Position (Unaudited) 1
Interim Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)2
Interim Condensed Consolidated Statements of Changes in Shareholders' Equity (Unaudited)
Interim Condensed Consolidated Statements of Cash Flows (Unaudited)4
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited)

#### Notice of No Auditor Review of Interim Condensed Financial Statements

In accordance with National Instrument 51-102, the Company discloses that its external auditors have not reviewed the accompanying interim condensed financial statements of Golden Leaf Holdings Ltd. as of September 30, 2018 and the notes to these interim condensed financial statements.

Interim Condensed Consolidated Statement of Financial Position (Unaudited) As at September 30, 2018 and December 31, 2017 (Expressed in U.S. dollars)

Accounts receivable     Note 6     1,206,512     3       Other receivables     198,674     198,674       Income tax recoverable     593,899     4       Sales tax recoverable     593,899     4       Biological assets     Note 7     216,060     -       Inventory     Note 7     3,201,889     3,6       Prepaid expenses and deposits     1,616,215     3       Assets held for sale     35,274     3       Total current assets     \$     20,099,140     \$     11,6       Property, plant and equipment     Note 8     6,144,273     5,9     1,971,398     31,9       Intangible assets     Note 9     26,006,313     26,2     75,7     10tal assets     \$     84,221,124     \$     75,7       LIABILITIES     Current portion of long-term debt     Note 11     29,511     1     1       Current portion of convertible debentures     carried at fair value     Note 10     -     2     2,778     -       Total current iabilities     \$     2,463,163     \$     3,3			Sept	ember 30, 2018	Dec	ember 31, 2017
Cash     \$     12,341,673     \$     6,0       Accounts receivable     Note 6     1,206,512     3     3       Other receivables     198,674     1     3     3       Income tax recoverable     686,944     4     4       Sales tax recoverable     593,899     4       Biological assets     Note 7     218,060     1       Inventory     Note 7     3,201,889     3,66       Prepaid expenses and deposits     1,616,215     3       Assets held for sale     35,274     3       Total current assets     \$     20,099,140     \$       Intangible assets     Note 9     26,006,313     26,62       Intangible assets     Note 9     26,006,313     26,62       CURRENT     Accounts payable and accrued liabilities     2,30,518     \$     2,8       Interest payable     10,956     -     -     2       Current portion of long-term debt     Note 11     29,511     1     1       Current portion of convertible debentures     2,463,163     \$	ASSETS					
Accounts receivable     Note 6     1,206,512     3       Other receivables     198,674     1       Income tax recoverable     593,899     4       Sales tax recoverable     593,899     4       Biological assets     Note 7     218,060     -       Inventory     Note 7     3,201,889     3,6       Prepaid expenses and deposits     1,616,215     3       Total current assets     \$     20,099,140     \$       Total current assets     \$     20,099,140     \$     11,6       Property, plant and equipment     Note 8     6,144,273     5,9     1,971,398     31,9       Total assets     Note 9     26,006,313     26,2     75,7     10       LIABILITIES     \$     84,221,124     \$     75,7       Current portion of fong-term debt     Note 10     -     2     2,8       Interest payable     Note 10     -     2     3,3       Current portion of convertible debentures     2,463,163     \$     3,3       Current portion of convertible debentures	CURRENT					
Other receivables     198,674       Income tax recoverable     686,944     4       Sales tax recoverable     593,899     4       Biological assets     Note 7     218,060     1       Inventory     Note 7     3,201,889     3,6       Prepaid expenses and deposits     1,616,215     3     3       Total current assets     \$     20,099,140     \$     11,6       Property, plant and equipment     Note 8     6,144,273     5,9       Intangible assets     Note 9     26,006,313     26,2       Goodwill     31,971,398     31,91     75,7       LIABILITIES     \$     84,221,124     \$     75,7       Current portion of long-term debt     Note 11     2,9,511     1     1       Current portion of convertible debentures     carried at fair value     Note 10     -     2       Current portion of convertible debentures     \$     2,463,163     \$     3,3       Total current liabilities     \$     2,463,163     \$     3,3       Total current liability     92,178	Cash		\$	12,341,673	\$	6,009,447
hcome tax recoverable     686,944     4       Sales tax recoverable     593,899     4       Biological assets     Note 7     218,060     7       hventory     Note 7     3,201,889     3,66       Prepaid expenses and deposits     1,616,215     3       Assets held for sale     35,274     3       Total current assets     \$     20,099,140     \$     11,6       Property, plant and equipment     Note 8     6,144,273     5,9     9       Intangible assets     Note 9     26,006,313     26,20     31,971,398     31,97       Total assets     Note 9     2,330,518     \$     2,8     75,7       LIABILITIES     \$     84,221,124     \$     75,7       Current portion of long-term debt     Note 11     29,511     1     1       Current portion of long-term debt     Note 10     -     2     2       Current portion of long-term debt     Note 10     -     2     2       Derivative liability     92,178     -     -     2     -	Accounts receivable	Note 6		1,206,512		377,746
Sales tax recoverable     593,899     4       Biological assets     Note 7     218,060     1       Inventory     Note 7     3,201,889     3,6       Prepaid expenses and deposits     1,616,215     3       Assets held for sale     35,274     3       Total current assets     \$     20,099,140     \$     11,6       Property, plant and equipment     Note 8     6,144,273     5,9     1       Intangible assets     Note 9     26,006,313     26,2     3       Goodwill     31,971,398     31,97     75,7     7     7       LIABILLITIES     \$     84,221,124     \$     75,7       LIABILLITIES     Current portion of long-term debt     Note 11     29,511     1       Current portion of convertible debentures     carried at fair value     2,178     1       Current portion of convertible debentures     \$     2,463,163     \$     3,33       Long term debt     Note 10     -     2     5     9       Note payable     Note 10     313,815     3 </td <td>Other receivables</td> <td></td> <td></td> <td>198,674</td> <td></td> <td>-</td>	Other receivables			198,674		-
Biological assets     Note 7     218,060       hventory     Note 7     3,201,889     3,6       Prepaid expenses and deposits     16,6215     3       Assets held for sale     32,274     3       Total current assets     \$     20,099,140     \$       Property, plant and equipment     Note 8     6,144,273     5,9       Intangible assets     Note 9     26,006,313     266,2       Goodwill     31,971,398     31,9     75,7       LIABILITIES     \$     84,221,124     \$     75,7       LIABILITIES     Current portion of long-term debt     Note 11     29,511     1       Current portion of convertible debentures     carried at fair value     Note 10     -     2       Derivative liabilities     \$     2,463,163     \$     3,3       Long term debt     Note 10     -1     31,815     3       Consideration payable     92,778     -     -       Total current liabilities     \$     2,463,163     \$     3,3       Long term debt     Note 10	Income tax recoverable			686,944		432,000
Inventory     Note 7     3,201,889     3,6       Prepaid expenses and deposits     1,616,215     3       Assets held for sale     35,274     3       Total current assets     \$     20,099,140     \$     11,6       Property, plant and equipment     Note 8     6,144,273     5,9       Intangible assets     Note 9     26,006,313     26,2       Goodwill     31,971,398     31,9       Total assets     \$     84,221,124     \$     75,7       LIABILITIES     \$     2,30,518     \$     2,8       Interest payable     10,956     \$     2,8       Current portion of long-term debt     Note 11     29,511     1       Current portion of convertible debentures     \$     2,463,163     \$     3,3       Long term debt     Note 10     313,815     3	Sales tax recoverable			593,899		442,832
Prepaid expenses and deposits     1.616,215     3       Assets held for sale     35,274     3       Total current assets     \$ 20,099,140     \$ 11,6       Property, plant and equipment     Note 8     6,144,273     5,9       Intangible assets     Note 9     26,006,313     26,2       Goodwill     31,971,398     31,9     1,9       Total assets     \$ 84,221,124     \$ 75,7       LIABILITIES     \$ 84,221,124     \$ 75,7       LIABILITIES     Current portion of long-term debt     Note 11     29,511     1       Accounts payable and accrued liabilities     2,330,518     \$ 2,8     1     1       Current portion of long-term debt     Note 11     29,511     1     1       Current portion of convertible debentures     carried at fair value     Note 10     -     2       Derivative liability     92,178     3     3     3     3       Long term debt     Note 11     64,455     3     3     3       Long term debt     Note 10     313,815     3     3     3	Biological assets	Note 7		218,060		90,627
Assets held for sale     35,274     3       Total current assets     \$ 20,099,140     \$ 11,6       Property, plant and equipment     Note 8     6,144,273     5,9       Intangible assets     Note 9     26,006,313     26,2       Goodw ill     31,971,398     31,97     75,7       LIABILITIES     \$ 84,221,124     \$ 75,7       LIABILITIES     \$ 84,221,124     \$ 75,7       LORRENT     Accounts payable and accrued liabilities     2,330,518     \$ 2,8       Neterest payable     10,956     -     -       Current portion of long-term debt     Note 11     29,511     1       Current portion of convertible debentures     -     2     -       carried at fair value     Note 10     -     2       Derivative liability     92,178     -     -       Total current liabilities     \$ 2,463,163     \$ 3,33       Long term debt     Note 11     64,455     -       Convertible debentures carried at fair value     Note 10     11,645,447     30,3       Convertible debentures carried at fair value	Inventory	Note 7		3,201,889		3,623,255
Total current assets     \$ 20,099,140     \$ 11,6       Property, plant and equipment Intangible assets     Note 8     6,144,273     5,9       Intangible assets     Note 9     26,006,313     26,2       Goodw III     31,971,398     31,9     31,9       Total assets     \$ 84,221,124     \$ 75,7       LIABILITIES     Current payable and accrued liabilities     2,330,518     \$ 2,8       Interest payable     10,956     1     1       Current portion of long-term debt     Note 11     29,511     1       Current portion of convertible debentures     carried at fair value     Note 10     -     2       Derivative liability     92,178     92,178     3     3,3       Long term debt     Note 11     64,455     3     3,3       Long term debt     Note 10     313,815     3     3     3       Convertible debentures carried at fair value     Note 10     11,645,447     30,3     3       Convertible debentures carried at fair value     Note 12     5,779,121     14,3       Total liabilities     \$ 29,793,35	Prepaid expenses and deposits			1,616,215		348,176
Property, plant and equipment     Note 8     6,144,273     5,9       Intangible assets     Note 9     26,006,313     26,2       Goodw ill     31,971,398     31,9       Total assets     \$ 84,221,124     \$ 75,7       LIABILITIES     Current     S     84,221,124     \$ 75,7       LIABILITIES     Current portion of long-term debt     Note 11     29,511     1       Accounts payable and accrued liabilities     2,330,518     \$ 2,8     Interest payable     10,956     1	Assets held for sale			35,274		305,274
Intangible assets Note 9 26,006,313 26,2 Goodw iil 31,971,398 31,9 Total assets \$ 84,221,124 \$ 75,7 LIABILITIES CURRENT Accounts payable and accrued liabilities 2,330,518 \$ 2,8 Interest payable Current portion of long-term debt Note 11 29,511 1 Current portion of convertible debentures carried at fair value Note 10 - 2 Derivative liabilities \$ 2,463,163 \$ 3,3 Long term debt Note 11 64,455 Note payable Note 10 313,815 3 Convertible debentures carried at fair value Note 10 313,815 3 Convertible debentures carried at fair value Note 10 11,645,447 30,3 Convertible debentures carried at fair value Note 10 11,645,447 30,3 Convertible debentures carried at fair value Note 10 11,645,447 30,3 Consideration payable Note 12 5,779,121 14,3 Total liabilities \$ 29,793,351 \$ 58,0 SHAREHOLDERS' EQUITY Share capital Note 13 138,249,400 \$ 108,5 Warrant reserve Note 14 4,078,120 5,0	Total current assets		\$	20,099,140	\$	11,629,357
Intangible assets Note 9 26,006,313 26,2 Goodw ill 31,971,398 31,9 Total assets \$ 84,221,124 \$ 75,7 LIABILITIES CURRENT Accounts payable and accrued liabilities 2,330,518 \$ 2,8 Interest payable Current portion of long-term debt Note 11 29,511 1 Current portion of convertible debentures carried at fair value Note 10 - 2 Derivative liabilities \$ 2,463,163 \$ 3,3 Long term debt Note 11 64,455 Note payable Note 10 313,815 3 Convertible debentures carried at fair value Note 10 313,815 3 Convertible debentures carried at fair value Note 10 11,645,447 30,3 Convertible debentures carried at fair value Note 10 11,645,447 30,3 Convertible debentures carried at fair value Note 10 11,645,447 30,3 Consideration payable Note 12 5,779,121 14,3 Total liabilities \$ 29,793,351 \$ 58,0 SHAREHOLDERS' EQUITY Share capital Note 13 138,249,400 \$ 108,5 Warrant reserve Note 14 4,078,120 5,0	Property plant and equipment	Noto 9		6 144 272		5,956,910
Goodwill     31,971,398     31,9       Total assets     \$ 84,221,124     \$ 75,7       LIABILITIES      75,7       LIABILITIES      75,7       Accounts payable and accrued liabilities     2,330,518     \$ 2,8       Interest payable     10,956     -       Current portion of long-term debt     Note 11     29,511     1       Current portion of convertible debentures     -     22       carried at fair value     Note 10     -     2       Derivative liabilities     \$ 2,463,163     \$ 3,3       Long term debt     Note 11     64,455     -       Note 10     313,815     3     3       Long term debt     Note 10     313,815     3       Note 10     313,815     3     3       Consideration payable     9,527,350     9,5       Warrant liabilities     \$ 29,793,351     \$ 58,0       SHAREHOLDERS' EQUITY     \$ 38,249,400     \$ 108,5       Share capital     Note 13     38,249,400     \$ 108,5       Warrant reserve     <						26,227,116
Total assets     \$     84,221,124     \$     75,7       LIABILITIES     CURRENT     Accounts payable and accrued liabilities     2,330,518     \$     2,88       Interest payable     10,956     10,955     10,955     10,955     10,955     10,955     10,955     10,95,50     10,95,50     10,95,50     10,95,50     10,95,50	5	Note 9				
LIABILITIES CURRENT Accounts payable and accrued liabilities 2,330,518 \$ 2,8 Interest payable Current portion of long-term debt Note 11 29,511 1 Current portion of convertible debentures carried at fair value Note 10 - 2 Derivative liability 92,178 Total current liabilities \$ 2,463,163 \$ 3,3 Long term debt Note 11 64,455 Note payable Note 10 313,815 3 Convertible debentures carried at fair value Note 10 11,645,447 30,3 Consideration payable 9,527,350 9,5 Warrant liability Note 12 5,779,121 14,3 Total liabilities \$ 29,793,351 \$ 58,0 SHAREHOLDERS' EQUITY Share capital Note 13 138,249,400 \$ 108,5 Warrant reserve Note 14 4,078,120 5,0			\$		¢	31,971,398 75,784,781
Current portion of convertible debentures carried at fair valueNote 10-2Derivative liability92,1781Total current liabilities\$ 2,463,163\$ 3,3Long term debtNote 1164,4551Note payableNote 10313,8153Convertible debentures carried at fair valueNote 1011,645,44730,3Consideration payable9,527,3509,5Warrant liabilities\$ 29,793,351\$ 58,0SHAREHOLDERS' EQUITYShare capitalNote 13138,249,400\$ 108,5Warrant reserveNote 144,078,120\$,0	Accounts payable and accrued liabilities Interest payable	Note 11		10,956	\$	2,867,735 48,524
carried at fair value     Note 10     -     2       Derivative liability     92,178     1       Total current liabilities     \$ 2,463,163     \$ 3,3       Long term debt     Note 11     64,455     -       Note payable     Note 10     313,815     3       Convertible debentures carried at fair value     Note 10     11,645,447     30,3       Consideration payable     9,527,350     9,55       Warrant liabilities     \$ 29,793,351     \$ 58,0       SHAREHOLDERS' EQUITY       Share capital     Note 13     138,249,400     \$ 108,5       Warrant reserve     Note 14     4,078,120     5,0	Current portion of long-term debt	Note 11				131,610
Derivative liability     92,178       Total current liabilities     \$ 2,463,163     \$ 3,3       Long term debt     Note 11     64,455       Note payable     Note 10     313,815     3       Convertible debentures carried at fair value     Note 10     11,645,447     30,3       Consideration payable     9,527,350     9,5       Warrant liabilities     \$ 29,793,351     \$ 58,0       SHAREHOLDERS' EQUITY       Share capital     Note 13     138,249,400     \$ 108,5       Warrant reserve     Note 14     4,078,120     \$,0	-					
Total current liabilities     \$ 2,463,163     \$ 3,3       Long term debt     Note 11     64,455       Note payable     Note 10     313,815     3       Convertible debentures carried at fair value     Note 10     11,645,447     30,3       Consideration payable     9,527,350     9,5       Warrant liability     Note 12     5,779,121     14,3       Total liabilities     \$ 29,793,351     \$ 58,0       SHAREHOLDERS' EQUITY       Share capital     Note 13     138,249,400     \$ 108,5       Warrant reserve     Note 14     4,078,120     5,0		Note 10		-		271,245
Long term debt     Note 11     64,455       Note payable     Note 10     313,815     3       Convertible debentures carried at fair value     Note 10     11,645,447     30,3       Consideration payable     9,527,350     9,5       Warrant liability     Note 12     5,779,121     14,3       Total liabilities     \$ 29,793,351     \$ 58,0       SHAREHOLDERS' EQUITY       Share capital     Note 13     138,249,400     \$ 108,5       Warrant reserve     Note 14     4,078,120     5,0	5			1		61,044
Note payable     Note 10     313,815     3       Convertible debentures carried at fair value     Note 10     11,645,447     30,3       Consideration payable     9,527,350     9,5       Warrant liability     Note 12     5,779,121     14,3       Total liabilities     \$ 29,793,351     \$ 58,0       SHAREHOLDERS' EQUITY       Share capital     Note 13     138,249,400     \$ 108,5       Warrant reserve     Note 14     4,078,120     5,0	Total current liabilities		\$	2,463,163	\$	3,380,158
Note payable     Note 10     313,815     3       Convertible debentures carried at fair value     Note 10     11,645,447     30,3       Consideration payable     9,527,350     9,5       Warrant liability     Note 12     5,779,121     14,3       Total liabilities     \$ 29,793,351     \$ 58,0       SHAREHOLDERS' EQUITY       Share capital     Note 13     138,249,400     \$ 108,5       Warrant reserve     Note 14     4,078,120     5,0	Long term debt	Note 11		64,455		80,381
Consideration payable     9,527,350     9,5       Warrant liability     Note 12     5,779,121     14,3       Total liabilities     \$ 29,793,351     \$ 58,0       SHAREHOLDERS' EQUITY       Share capital     Note 13     138,249,400     \$ 108,5       Warrant reserve     Note 14     4,078,120     5,0	-	Note 10		313,815		389,916
Warrant liability     Note 12     5,779,121     14,3       Total liabilities     \$ 29,793,351     \$ 58,0       SHAREHOLDERS' EQUITY     Share capital     Note 13     138,249,400     \$ 108,5       Warrant reserve     Note 14     4,078,120     5,0	Convertible debentures carried at fair value	Note 10		11,645,447		30,360,225
Total liabilities     \$ 29,793,351     \$ 58,0       SHAREHOLDERS' EQUITY     Share capital     Note 13     138,249,400     \$ 108,5       Warrant reserve     Note 14     4,078,120     5,0	Consideration payable			9,527,350		9,527,350
Total liabilities     \$ 29,793,351     \$ 58,0       SHAREHOLDERS' EQUITY     Share capital     Note 13     138,249,400     \$ 108,5       Warrant reserve     Note 14     4,078,120     5,0	Warrant liability	Note 12		5,779,121		14,300,616
Share capital     Note 13     138,249,400     \$ 108,5       Warrant reserve     Note 14     4,078,120     5,0			\$		\$	58,038,646
Warrant reserve     Note 14     4,078,120     5,0	SHAREHOLDERS' EQUI	ΤY				
Warrant reserve     Note 14     4,078,120     5,0	Share capital	Note 13		138,249,400	\$	108,552,681
	•					5,083,561
		Note 15				1,087,640
Contributed surplus 59,940	•					59,940

Accumulated other comprehensive (gain) loss(35,960)Deficit(91,041,392)Total shareholders' equity\$ 54,427,773Total liabilities and shareholders' equity\$ 84,221,124

Going Concern (Note 2)

Commitments (Note 16)

Segmented Information (Note 21)

Subsequent events (Note 23)

See accompanying notes to consolidated financial statements.

9,828

(97,047,515)

17,746,135

75,784,781

\$

\$

Interim Condensed Consolidated Statement of Operations and Comprehensive Gain (Loss) (Unaudited) For the three and nine months ended September 30, 2018 and 2017 (Expressed in U.S. dollars)

			For the three Septen				For the nine r Septerr		
			2018		2017		2018		2017
Revenues									
Product sales		\$	5,104,251	\$	3,078,891	\$	11,958,978	\$	7,427,378
Royalties			-		50,000		-		50,000
Consulting revenue			8,662		-		35,838		-
Total Revenue		\$	5,112,913	\$	3,128,891	\$	11,994,816	\$	7,477,378
Inventory expensed to cost of sales			3,825,330		2,315,490		9,579,838		5,684,389
Production costs			476,512		181,213		887,739		520,278
Gross margin, excluding fair value items			811,071		632,188		1,527,239		1,272,711
Fair value changes in biological assets included			,		,		.,,		.,,
in inventory sold			(91,672)		-		37,976		-
(Gain) Loss on changes in fair value of biological assets	Note 7		458,542		(99,000)		(247,715)		(99,000)
Gross profit		\$	444,201	\$	731,188	\$	1,736,978	\$	1,371,711
-									
Expenses General and administration			3,182,236		3,313,869		9,248,288		6,970,399
Share based compensation	Note 15		539,758		676.018		2.183.179		1.052.587
Professional fees paid with equity instruments			-		116,588		2,103,173		284,079
Sales and marketing			557,500		319,665		1,381,552		885,877
Depreciation and amortization	Note 8, 9		376,977		225,922		1,080,772		359,225
Total expenses	11010 0, 0	\$	4,656,471	\$	4,652,062	\$	13,893,791	\$	9,552,167
Loss before undernoted items		\$	(4,212,270)	\$	(3,920,874)	\$	(12,156,813)	\$	(8,180,456)
		Ψ		Ψ	<u> </u>	<u> </u>		Ψ	
Interest (income) expense, net			(31,280)		556,427		884,295		1,413,859
Transaction costs			454,292		2,365,821		926,192		2,365,821
Loss on disposal of assets			-		25,500		5,000		319,700
Impairment of financing lease receivable			-		27,422		-		82,266
Other (income) loss			(12,410)		37,296		(134,813)		200,124
(Gain) Loss on change in fair value of warrant liability	Note 12		1,372,824		(2,841,983)		(9,254,878)		(3,080,362)
(Gain) Loss on change in fair value of liabilities	Note 10		(506,686)		(1,148,020)		(10,477,289)		(2,733,810)
Gain (loss) before income taxes		\$	(5,489,010)	\$	(2,943,337)	\$	5,894,680	\$	(6,748,054)
Current income tax expense			3,842		219,587		12,276		419,587
Net Gain (Loss)		\$	(5,492,852)	\$	(3,162,924)	\$	5,882,404	\$	(7,167,641)
Other comprehensive loss									
Cumulative translation adjustment			(7,475)		-	\$	45,788	\$	-
Comprehensive gain (loss)		\$	(5,485,377)	\$	(3,162,924)	\$	5,836,616	\$	(7,167,641)
Basic and diluted gain (loss) per share		\$	(0.01)	\$	(0.01)	\$	0.01		(0.04)
Weighted average number of common shares outstanding	1		580,321,291		345,710,474		563,832,540		203,386,663

See accompanying notes to consolidated financial statements.

Interim Condensed Consolidated Statement of Changes in Shareholders' Equity (Unaudited)

For the nine months ended September 30, 2018 and 2017

(Expressed in U.S. dollars)

			Warrant	Sto	ock options	Sh	ares to be	Со	ntributed	Accun	nulated other		
	S	hare Capital	Reserve		reserve		issued	s	surplus	compre	hensive loss	Deficit	Total
Balance, January 1, 2017	\$	34,282,314	\$ 3,501,409	\$	993,211	\$	267,701	\$	59,940	\$	(530,000)	\$ (41,510,472)	\$ (2,935,897)
Issuance of common shares		56,431,800	-		-		(267,701)		-		-	-	56,164,099
Issuance of warrants and broker units		-	199,077		-		-		-		-	-	199,077
Exercise of warrants and options for common shares		276,097	(141,940)		(20,600)		-		-		-	-	113,557
Issuance of share-based compensation		569,808	-		511,593		-		-		-	-	1,081,401
Expiry of warrants and stock options		-	-		-		-		-		-	-	-
Net loss and comprehensive loss for the year		-	-		-		-		-		-	(7,167,641)	(7,167,641)
Balance at September 30, 2017	\$	91,560,019	\$ 3,558,546	\$	1,484,204	\$	-	\$	59,940	\$	(530,000)	\$ (48,678,113)	\$ 47,454,596

			Warrant	St	ock options	S	Shares to be	Co	ontributed	Accumulated	d other		
	S	hare Capital	Reserve		reserve		issued	5	surplus	comprehensi	ve loss	Deficit	Total
Balance, January 1, 2018	\$	108,552,681	\$ 5,083,561	\$	1,087,640	9	\$-	\$	59,940	\$	9,828	\$ (97,047,515)	\$ 17,746,135
Issuance of common shares (note 13)		17,170,388	-		-		-		-		-	-	17,170,388
Issuance of warrants and broker units (note 14)		-	426,367		-		-		-		-	-	426,367
Exercise of warrants and options for common shares (notes 14, 15)		12,416,403	(1,431,808)		-		-		-		-	-	10,984,595
Issuance of share-based compensation (note 15)		109,928	-		2,153,744		-		-		-	-	2,263,672
Expiry of warrants and stock options		-	-		(123,719)	)	-		-		-	123,719	-
Net loss and comprehensive loss for the period		-	-		-		-		-	(	(45,788)	5,882,404	5,836,616
Balance at September 30, 2018	\$	138,249,400	\$ 4,078,120	\$	3,117,665	Ś	\$-	\$	59,940	\$ (	(35,960)	\$ (91,041,392)	\$ 54,427,773

See accompanying notes to consolidated financial statements.

Interim Consolidated Statement of Cash Flows (Unaudited) For the nine month periods ended September 30, 2018 and 2017 (Expressed in U.S. dollars)

2016     2017       Cash provide by (used in):			For the nine m Septem	
Operating activities:     S     5.882.404     \$     (7,167,64)       Net Gain (Loss)     S     5.882.404     \$     (7,167,64)       Depreciation of property, plant and equipment     Note 8     859,969     211,95       Amortizaton of intangible assets     220,803     -     -       Loss on disposal of assets     5,000     319,70     -       Income taxes paid     (324,620)     -     -       Income taxes paid     (324,620)     -     -       Professional fees paid with equity instruments     Note 15     2,153,744     676,041       Cigain/bass on fair value adjustment to warrants liability     Note 12     (9,254,878)     (3,080,36)       Giain/infair value of biological assets     Note 7     129,210     -     -       Cigain of fair value adjustment to debt     Note 7     192,100     -     -       Charne cash transactions     (33,625)     (8,82,33)     Chare cash transactions     (33,625)     (8,82,33)       Charne cash transactions     (33,625)     (10,60,33)     (10,60,33)     (10,60,33)     (10,60,33)     (10,60,33) </th <th></th> <th></th> <th></th> <th></th>				
Note Gain (Loss)     \$     5,882,404     \$     (7,167,44)       Depreciation of property, plant and equipment     Note 8     859,969     211,95       Arrontization of intragible assets     20,003     -     -       Loss on disposal of assets     5,000     319,70     -       Interset sexpense     666,676     419,35     -       Share based compensation     Note 15     2,153,744     676,01       Professional fees paid with equity instruments     -     -     166,676       Giain/loss on fair value adjustment to debt     Note 10     (10,705,635)     (3,080,36       Giain on fair value adjustment to debt     Note 7     (247,715)     (99,00)       Reserve for obsolder inventory     Note 7     12,100     -     82,26       Other non-cash transactions     (339,625)     (82,33)     Chart receivable     -     82,26       Other receivables     Note 7     120,00     -     82,26       Other non-cash transactions     (339,625)     (82,33)     Chart receivable     -     62,226       Other receivables     Note 7     <	Cash provide by (used in):			
Depreciation of property, plant and equipment     Note 8     869,969     211,95       Amoritzaton of intangble assets     220,803     -     -       Loss on disposal of assets     5,000     319,70       Interest expense     884,295     1,413,85       Income tax expense     69,676     419,35       Bad debt expense     141,325     -       Share based compensation     Note 15     2,153,744     676,01       Professional fees paid with equip instruments     -     116,56     (Gain)/loss on fair value adjustment to debt     Note 12     (2,254,878)     (3,080,36       (Gain)/loss on fair value adjustment to debt     Note 7     (24,77,15)     (99,00     -       Reserve for obsolete inventory     Note 7     (24,77,15)     (99,00     -     mpairment of finance lease receivable     -     82,26       Cher non-cash transactions     (33,625)     (82,33     Cher receivabale     -     82,26       Other receivabale     -     120,282     -     -     82,26       Cher non-cash transactions     (33,625)     (82,33     Cher receivabale     -	Operating activities:			
Amortization of intrangible assets     220,803     -       Loss on disposal of assets     5,000     319,70       Interest expense     68,6295     1,413,85       Income taxes paid     (324,620)     -       Income taxes paid     (324,620)     -       Income taxes paid     (324,620)     -       Income taxes paid     (141,325     -       Share based compensation     Note 15     2,153,744     676,01       Professional fees paid with equity instruments     -     116,58     (3,000,35       (Gain)/loss on fair value adjustment to debt     Note 10     (10,705,635)     (1,148,02       Transaction cost     926,192     2,365,82     Gaia on fair value of biological assets     Note 7     192,100     -       Reserve for obsolete inventory     Note 7     192,100     -     82,26       Other non-cash transactions     (330,625)     (82,33)       Charges in working capital items     -     82,266       Accounts receivable     Note 7     120,282     -       Inventory     Note 7     220,266     (1,68,36	Net Gain (Loss)		\$ 5,882,404	\$ (7,167,641
Amortization of intrangible assets     220,803     -       Loss on disposal of assets     5,000     319,70       Interest expense     68,6295     1,413,85       Income taxes paid     (324,620)     -       Income taxes paid     (324,620)     -       Income taxes paid     (324,620)     -       Income taxes paid     (141,325     -       Share based compensation     Note 15     2,153,744     676,01       Professional fees paid with equity instruments     -     116,58     (3,000,35       (Gain)/loss on fair value adjustment to debt     Note 10     (10,705,635)     (1,148,02       Transaction cost     926,192     2,365,82     Gaia on fair value of biological assets     Note 7     192,100     -       Reserve for obsolete inventory     Note 7     192,100     -     82,26       Other non-cash transactions     (330,625)     (82,33)       Charges in working capital items     -     82,266       Accounts receivable     Note 7     120,282     -       Inventory     Note 7     220,266     (1,68,36	Depreciation of property, plant and equipment	Note 8	859,969	211,957
Interest expense     884,295     1,413,85       Income taxes paid     (324,620)     -       Income taxe expense     69,676     1413,35       Bad debt expense     141,325     -       Share based compensation     Note 15     2,153,744     676,01       Professional fees paid with equity instruments     -     116,58     (3,080,38       (Gain/Moss on fair value adjustment to warrants liability     Note 12     (9,254,878)     (3,080,38       (Gain on fair value adjustment to debt     Note 10     (10,705,635)     (1,148,02       Transaction cost     926,192     2,365,82     Gain on fair value adjustment to debt     Note 7     (247,715)     (99,00       Reserve for obsolete inventory     Note 7     129,2100     -     82,263       Charner cash transactions     (333,625)     (82,263     (83,414)     369,33       Share star recoverable     (151,067)     (105,03     Accounts receivable     (151,067)     (105,03       Accounts receivable     Note 7     120,282     -     -       Inventory     Note 7     120,282     - <td< td=""><td></td><td></td><td>220,803</td><td>-</td></td<>			220,803	-
Income taxes paid     (324,620)	Loss on disposal of assets		5,000	319,700
Income tax expense     69,676     419,35       Bad debt expense     141,325     -       Share based compensation     Note 15     2,153,744     676,01       Professional fees paid with equity instruments     -     116,58     (3,080,36       (Gain/Joss on fair value adjustment to warrants liability     Note 12     (9,254,878)     (3,080,36       (Gain/Joss on fair value adjustment to debt     Note 10     (10,705,635)     (1,148,02       Transaction cost     926,192     2,365,82     Gain on fair value adjustment to debt     Note 7     (247,715)     (99,00)       Reserve for obsolete inventory     Note 7     129,2100     -     Reserve for obsolete inventory     Note 7     129,2100     -       Accounts receivables     (10,86,74)     339,325     (82,33)     (82,33)     (84,33)     -     105,033     Salesta krecoverable     (11,68,36,33)     Salesta krecoverable     (11,68,36,93)     -     -     70,039,13,33     Salesta krecoverable     (11,68,36,93)     -     -     -     -     -     -     -     -     -     -     -     -	Interest expense		884,295	1,413,85
Bad debt expense     141,325       Share based compensation     Note 15     2,153,744     676,01       Professional fees paid with equip instruments     -     116,58     (Gain)/loss on fair value adjustment to debt     Note 12     (9,254,878)     (3,080,36       (Gain)/loss on fair value adjustment to debt     Note 10     (10,705,635)     (1,148,02)     2,365,82       Gain on fair value of biological assets     Note 7     192,100     -     82,26       Gain on fair value of biological assets     Note 7     192,100     -     82,26       Other non-cash transactions     (333,625)     (82,33     Charges in working capital item s     -     82,26       Accounts receivable     (151,067)     (105,03     -     141,325     -       Accounts payable and accrued liabilities     (217,80,04)     2,394,12     -     -       Biological assets     Note 7     120,282     -     -     -       Inventory     Note 7     120,282     -     -     -       Inventory     Note 7     120,282     -     -     -       Dep	Income taxes paid		(324,620)	-
Share based compensation     Note 15     2,153,744     676,01       Professional fees paid with equity instruments     -     -     116,58       (Gain)/loss on fair value adjustment to warrants liability     Note 12     (9,254,878)     (3,080,36)       (Gain)/loss on fair value adjustment to debt     Note 10     (10,705,635)     (1,148,02)       Transaction cost     926,1192     2,366,52       Gain on fair value of biological assets     Note 7     192,100     -       Impairment of finance lease receivable     -     82,266     (970,091)     3,43       Other non-cash transactions     (198,674)     369,93     (151,067)     (105,03)       Accounts receivable     Note 6     (970,091)     3,43     (198,674)     2,394,12       Biological assets     Note 7     120,282     -     -     Inventory     (10,00,302)     -       Inventory     Note 7     120,282     -     -     (198,033)     (5,007,69)       Mice 10     (10,43,075)     \$     (1,003,02)     -     -     (237,08)       Note 7     120,282     <	Income tax expense		69,676	419,35
Professional fees paid with equity instruments     -     116,58       (Gain)/loss on fair value adjustment to warrants liability     Note 12     (9,254,878)     (3,080,36       (Gain)/loss on fair value adjustment to debt     Note 10     (10,705,635)     (1,148,02)       Transaction cost     926,192     2,365,82     Gain on fair value of biological assets     Note 7     (247,715)     (199,00)       Reserve for obsoletic inventory     Note 7     192,100     -     82,266       Other non-cash transactions     (393,625)     (82,33)     (84,33)       Changes in working capital items     (151,667)     (105,03)     34       Accounts receivable     Note 6     (970,091)     3,43       Other receivabales     (151,667)     (105,03)       Accounts payable and accrued liabilities     Note 7     120,282     -       Inventory     Note 7     229,266     (1,98,86)       Prepaid expenses and deposits     (203,022)     -     -       Cash used in operating activities     \$     (11,043,075)     \$     (5,007,69)       NVESTING ACTITIVES     Deposits on property, plant and equipme	Bad debt expense		141,325	-
(Gain)/loss on fair value adjustment to varrants liability     Note 12     (9,254,878)     (3,080,36       (Gain)/loss on fair value adjustment to debt     Note 10     (10,705,635)     (1,148,02       Transaction cost     926,192     2,365,82     Gain on fair value of biological assets     Note 7     (247,715)     (99,00       Reserve for obsolete inventory     Note 7     192,100     -     82,26       Other non-cash transactions     (393,625)     (82,33)       Charges in working capital items     (198,674)     369,33       Accounts receivable     (151,067)     (105,03)       Other receivabales     (151,067)     (105,03)       Accounts payable and accrued liabilities     (278,604)     2,394,12       Biological assets     Note 7     120,282     -       Inventory     Note 7     120,282     -       Tas used in operating activities     \$ (11,043,075) \$ (5,007,68)       NUESTING ACTITIVES     (236,03)     -       Deposits on property, plant and equipment     Note 8     (1,268,33)     -       Purchases of intongible assets     -     -     (21,750,00) <	Share based compensation	Note 15	2,153,744	676,018
(Gain)/loss on fair value adjustment to debt     Note 10     (10.705,635)     (1,148,02       Transaction cost     926,192     2,2365,82     2,2365,82     2,2365,82     2,2365,82     2,2365,82     2,2365,82     2,2365,82     2,2365,82     2,2365,82     2,2365,82     2,2365,82     2,2365,82     2,2365,82     2,2365,82     2,2365,82     2,2365,82     2,2365,82     2,2365,82     2,2365,82     3,336     2,2365,82     3,336     2,2365,82     3,336     2,336,82     3,336     2,338,82     3,433     Chter rom-cash transactions     105,033     3,433     3,433     3,433     3,433     3,433     3,433     3,433     3,433     3,433     3,433     3,433     3,433     3,433     3,442     2,394,12     3,649,142,169,163,163     3,649,142,163,143,143     1,648,95     1,1043,075     \$     5,007,693     1,1043,075     \$     5,007,693     1,1043,075     \$     5,007,693     1,1048,075     \$     5,007,693     1,1048,075     \$     5,007,693     1,1043,075     \$     5,007,693     1,1043,075     \$     5,007,693     1,1043,075 <td< td=""><td>Professional fees paid with equity instruments</td><td></td><td>-</td><td>116,58</td></td<>	Professional fees paid with equity instruments		-	116,58
Transaction cost     926,192     2,365,82       Gain on fair value of biological assets     Note 7     (247,715)     (99,00)       Reserve for obsolete inventory     Note 7     132,100     -     82,266       Other non-cash transactions     (333,625)     (82,33)     (82,33)       Charges in working capital items     -     82,266     (198,674)     369,933       Sales tax receivable     (151,067)     (105,03)     Accounts payable and accrued liabilities     (278,804)     2,394,12       Biological assets     Note 7     120,282     -     -       Inventory     Note 7     229,266     (1,683,36     -       Prepaid expenses and deposits     (203,022)     -     -     -       Roceeds from disposal of property plant and equipment     Note 8     -     (1,548,92)     -     -     -     -     -     -	(Gain)/loss on fair value adjustment to warrants liability	Note 12	(9,254,878)	(3,080,362
Gain on fair value of biological assets     Note 7     (247,715)     (99,00       Reserve for obsolete inventory     Note 7     192,100     -       Impairment of finance lease receivable     -     -     82,26       Other non-cash transactions     (393,625)     (82,33       Changes in working capital items     (184,674)     369,33       Accounts receivable     (151,067)     (105,03       Chor non-cash transactions     (278,804)     2,394,12       Biological assets     Note 7     120,282     -       Inventory     Note 7     229,266     (168,86,74)       Inventory     Note 7     229,266     (16,98,36,74)       Propaid expenses and deposits     (203,022)     -     -       Cash used in operating activities     \$     (11,043,075)     \$     (5,007,69       NVESTING ACTITIVES     -     (156,039)     -     -     706,93       Purchase of property, plant and equipment     Note 8     (1,052,332)     (1,164,825     -       Payment of deposits and retainers     (1,268,039)     -     -     -	(Gain)/loss on fair value adjustment to debt	Note 10	(10,705,635)	(1,148,02
Reserve for obsolete inventory     Note 7     192,100     -       Impairment of finance lease receivable     -     82,26       Other non-cash transactions     (393,625)     (82,33)       Changes in working capital items     (393,625)     (82,33)       Accounts receivable     (198,674)     369,393       Sales tax recoverable     (151,067)     (105,03)       Accounts payable and accrued liabilities     (278,804)     22,994,12       Biological assets     Note 7     229,266     (1,698,36)       Prepaid expenses and deposits     (203,022)     -     -       Cash used in operating activities     \$     (11,043,075)     \$     (5,007,69)       NVESTING ACTITIVES     E     -     (357,08)     -     (1,548,92)       Proceeds from disposal of property plant and equipment     Note 8     (1,052,332)     (1,1648,35)     -       Payment of deposits and retainers     (1,268,039)     -     -     -       Payment of accrued transaction costs     (38,413)     -     -     -       Note 13     21,669,001     26,956,97     -	Transaction cost		926,192	2,365,82
Impairment of finance lease receivable     -     82,26       Other non-cash transactions     (393,625)     (82,33       Changes in working capital items     -     84,000       Accounts receivables     (198,674)     369,93       Sales tax recoverable     (151,067)     (105,03       Accounts payable and accrued liabilities     (278,804)     2,394,12       Biological assets     Note 7     120,282     -       Inventory     Note 7     229,266     (1698,36       Prepaid expenses and deposits     (203,022)     -     -       Cash used in operating activities     \$     (11,043,075)     \$     (5,007,68)       NVESTING ACTITIVES     -     -     -     -       Deposits on property, plant and equipment     Note 8     -     -     -       Proceeds from disposal of property plant and equipment     Note 8     -     -     -       Payment of deposits and retainers     (1,268,039)     -     -     -       Payment of deposits and retainers     -     -     -     -       Payment of deposits and ret	Gain on fair value of biological assets	Note 7	(247,715)	(99,00
Other non-cash transactions     (393,625)     (82,33       Changes in working capital items     -     -       Accounts receivable     Note 6     (970,091)     3,43       Other receivabales     (198,674)     369,93       Sales tax recoverable     (151,067)     (105,03       Accounts payable and accrued liabilities     (278,804)     2,394,12       Biological assets     Note 7     120,282     -       Inventory     Note 7     229,266     (1,698,36       Prepaid expenses and deposits     (203,022)     -     -       Cash used in operating activities     \$     (11,043,075)     \$     (5,007,69       NVESTING ACTITIVES     -     -     (357,08     -     -     706,93       Purchase of property, plant and equipment     Note 8     -     -     -     706,93       Investment in MWGC     -     -     -     -     -     -       Payment of deposits and retainers     (1,268,039)     -     -     -     -       Purchases of intangible assets     -     -	Reserve for obsolete inventory	Note 7	192,100	-
Changes in working capital itemsAccounts receivableNote 6(970,091)3,43Other receivabales(198,674)369,93Sales tax recoverable(151,067)(105,03Accounts payable and accrued liabilities(278,804)2,394,12Biological assetsNote 7120,282-InventoryNote 7229,266(1,698,36Prepaid expenses and deposits(203,022)-Cash used in operating activities\$ (11,043,075)\$ (5,007,69NVESTING ACTITIVESS(1,052,332)(1,548,92Poceeds from disposal of property plant and equipmentNote 8(1,052,332)(1,548,92Proceeds from disposal of property plant and equipmentNote 8(1,052,332)(1,688,039)Purchases of intangible assetsPayment of deposits and retainers(1,268,039)Payment of accrued transaction costs(38,413)Net cash outflow on acquisition of subsidiaries\$ (2,358,784)\$ (24,117,93TNANCING ACTIVITIES(603,00)Repayment of convertible notes(603,00)Repayment of convertible notes(603,00)Repayment of neated party loan(500,00)Cash provided by financing activities\$ 19,734,085\$ 25,819,37Repayment of convertible notes(500,00)Cash period\$ 0,332,226\$ (3,306,25Cash, beginning of period\$ 12,341,673\$ 6,	Impairment of finance lease receivable		-	82,26
Accounts receivable     Note 6     (970,091)     3,43       Other receivabales     (198,674)     369,93       Sales tax recoverable     (151,067)     (105,03       Accounts payable and accrued liabilities     (278,804)     2,394,12       Biological assets     Note 7     120,282     -       Inventory     Note 7     229,266     (1,698,36       Prepaid expenses and deposits     (203,022)     -     -       Cash used in operating activities     \$     (11,043,075)     \$     (5,007,69       NVESTING ACTITIVES     Deposits on property, plant and equipment     Note 8     -     (357,08       Purchase of property, plant and equipment     Note 8     (1,052,332)     (1,548,92       Proceeds from disposal of property plant and equipment     Note 8     (1,021,043)     -       Payment of deposits and retainers     (1,268,039)     -     -       Payment of accrued transaction costs     (38,413)     -     -       Net cash outflow on acquisition of subsidiaries     -     (21,750,00     -       Cash used in investment activities     \$     (2,358,784	Other non-cash transactions		(393,625)	(82,33
Accounts receivable     Note 6     (970,091)     3,43       Other receivabales     (198,674)     369,93       Sales tax recoverable     (151,067)     (105,03       Accounts payable and accrued liabilities     (278,804)     2,394,12       Biological assets     Note 7     120,282     -       Inventory     Note 7     229,266     (1,698,36       Prepaid expenses and deposits     (203,022)     -     -       Cash used in operating activities     \$     (11,043,075)     \$     (5,007,69       NVESTING ACTITIVES     Deposits on property, plant and equipment     Note 8     -     (357,08       Purchase of property, plant and equipment     Note 8     (1,052,332)     (1,548,92       Proceeds from disposal of property plant and equipment     Note 8     (1,021,043)     -       Payment of deposits and retainers     (1,268,039)     -     -       Payment of accrued transaction costs     (38,413)     -     -       Net cash outflow on acquisition of subsidiaries     -     (21,750,00     -       Cash used in investment activities     \$     (2,358,784	Changes in working capital items			
Other receivabales     (198,674)     369,93       Sales tax recoverable     (151,067)     (105,03       Accounts payable and accrued liabilities     (278,804)     2,394,12       Biological assets     Note 7     120,282     -       Inventory     Note 7     229,266     (1,698,36       Prepaid expenses and deposits     (203,022)     -     -       Cash used in operating activities     \$ (11,043,075)     \$ (5,007,69       NVESTING ACTITIVES     -     (357,08       Purchase of property, plant and equipment     Note 8     -     (357,08       Purchase of property, plant and equipment     Note 8     (1,052,332)     (1,168,85       Payment of deposits and retainers     (1,268,039)     -     -       Payment of accrued transaction costs     (38,413)     -     -       Payment of accrued transaction costs     (38,413)     -     -       Suance of common shares     Note 13     (1,021,949)     -       Investment of long-term debt     (194,126)     (34,59     -       Investment of long-term debt     (194,126)     (34,59		Note 6	(970.091)	3.43
Sales tax recoverable   (151,067)   (105,03)     Accounts payable and accrued liabilities   (278,804)   2,394,12     Biological assets   Note 7   120,282   -     Inventory   Note 7   229,266   (1698,36)     Prepaid expenses and deposits   (203,022)   -     Cash used in operating activities   \$ (11,043,075)   \$ (5,007,69)     NVESTING ACTITIVES   Deposits on property, plant and equipment   Note 8   -   (135,08)     Purchase of property, plant and equipment   Note 8   (1,052,332)   (1,548,92)     Proceeds from disposal of property plant and equipment   -   706,93     Investment in MMGC   -   (1,168,85)     Payment of deposits and retainers   (1,268,039)   -     Payment of accrued transaction costs   (38,413)   -     Net cash outflow on acquisition of subsidiaries   -   (21,750,00)     Cash used in investment activities   \$ (2,358,784)   \$ (24,117,39)     TNANCING ACTIVITIES   suance of common shares   Note 13   (1,021,949)   -     Repayment of long-term debt   (194,126)   (34,59)   -   (603,00)			,	-
Accounts payable and accrued liabilities   (278,804)   2,394,12     Biological assets   Note 7   120,282   -     Inventory   Note 7   229,266   (1,698,36     Prepaid expenses and deposits   (203,022)   -     Cash used in operating activities   \$ (11,043,075)   \$ (5,007,69     NVESTING ACTITIVES   -   (357,08     Purchase of property, plant and equipment   Note 8   -   (357,08     Purchase of property, plant and equipment   Note 8   (1,052,332)   (1,548,92     Proceeds from disposal of property plant and equipment   -   706,93     Investment in MMGC   -   -   (1,168,85     Payment of deposits and retainers   (1,268,039)   -   -     Payment of accrued transaction costs   (38,413)   -   -     Net cash outflow on acquisition of subsidiaries   -   (21,750,00   26,956,97     Nakt CINCING ACTIVITIES   -   -   (603,00     Issuance of common shares   Note 13   21,669,001   26,956,97     Repayment of long-term debt   (194,126)   (34,59     Interest paid   (718,841)				-
Biological assets     Note 7     120,282     -       Inventory     Note 7     229,266     (1,698,36       Prepaid expenses and deposits     (203,022)     -       Cash used in operating activities     \$     (11,043,075)     \$     (5,007,69)       NVESTING ACTITIVES      (1,548,92)     (1,548,92)     (1,548,92)       Proceeds from disposal of property plant and equipment     Note 8     (1,052,332)     (1,548,92)       Proceeds from disposal of property plant and equipment     Note 8     (1,268,039)     -       Payment of deposits and retainers     (1,268,039)     -     -       Payment of accrued transaction costs     (38,413)     -     -       Payment of accrued transaction costs     (2,358,784)     \$     (24,117,93)       TNANCING ACTIVITIES     -     -     -     -       Issuance of common shares     Note 13     (1,021,949)     -     -       Repayment of long-term debt     (194,126)     (34,59)     -     -       Repayment of related party loan     -     (500,00)     -     -     (500,00)				
Inventory     Note 7     229,266     (1,698,36       Prepaid expenses and deposits     (203,022)     -       Cash used in operating activities     \$ (11,043,075)     \$ (5,007,69)       NVESTING ACTITIVES     -     (357,08)       Purchase of property, plant and equipment     Note 8     -     (357,08)       Purchase of property, plant and equipment     Note 8     (1,052,332)     (1,148,92)       Proceeds from disposal of property plant and equipment     -     706,93       Investment in MMGC     -     (1,168,85)       Payment of deposits and retainers     (1,268,039)     -       Purchases of intangible assets     -     -       Payment of accrued transaction costs     (38,413)     -       Net cash outflow on acquisition of subsidiaries     -     (21,750,00)       Cash used in investment activities     \$ (2,358,784)     \$ (24,117,93)       TNANCING ACTIVITIES     -     -     -       Issuance of common shares     Note 13     (1,021,949)     -       Repayment of long-term debt     (194,126)     (34,59)     -       Repayment of related party		Note 7	,	-
Prepaid expenses and deposits     (203,022)       Cash used in operating activities     \$ (11,043,075)     \$ (5,007,69)       NVESTING ACTITIVES      (11,043,075)     \$ (357,08)       Purchase of property, plant and equipment     Note 8     -     (357,08)       Purchase of property, plant and equipment     Note 8     (1,052,332)     (1,548,92)       Proceeds from disposal of property plant and equipment     -     706,93       Investment in MMGC     -     (1,168,85)       Payment of deposits and retainers     (1,268,039)     -       Payment of accrued transaction costs     (38,413)     -       Net cash outflow on acquisition of subsidiaries     -     (21,750,00)       Cash used in investment activities     \$ (2,358,784)     \$ (24,117,93)       TNANCING ACTIVITIES     -     -       Issuance of common shares     Note 13     (1,021,949)     -       Repayment of long-term debt     (194,126)     (34,59)     -       Neterst paid     (718,841)     -     (500,00)     -       Repayment of related party loan     -     (500,00)     -     (500,00	-	Note 7		(1,698,36
Cash used in operating activities     \$ (11,043,075)     \$ (5,007,69       NVESTING ACTITIVES     Deposits on property, plant and equipment     Note 8     -     (357,08       Purchase of property, plant and equipment     Note 8     (1,052,332)     (1,548,92       Proceeds from disposal of property plant and equipment     -     706,93       Investment in MMGC     -     (1,168,85       Payment of deposits and retainers     (1,268,039)     -       Purchases of intangible assets     -     -       Payment of accrued transaction costs     (38,413)     -       Net cash outflow on acquisition of subsidiaries     2     (24,177,900       Cash used in investment activities     \$ (2,358,784)     \$ (24,117,93       TNANCING ACTIVITIES     \$     (24,117,93       Issuance of common shares     Note 13     21,669,001     26,956,97       Payment of share issuance costs     Note 13     (1,021,949)     -       Repayment of share issuance costs     Note 13     (1,021,949)     -       Repayment of convertible notes     -     (500,00     -     (500,00       Repayment of related party l	Prepaid expenses and deposits			-
Deposits on property, plant and equipmentNote 8-(357,08Purchase of property, plant and equipmentNote 8(1,052,332)(1,548,92)Proceeds from disposal of property plant and equipment-706,93Investment in MMGC-(1,168,85)Payment of deposits and retainers(1,268,039)-Purchases of intangible assetsPayment of accrued transaction costs(38,413)-Net cash outflow on acquisition of subsidiaries-(21,750,00)Cash used in investment activities\$(2,358,784)\$INANCING ACTIVITIES(603,00)Repayment of share issuance costsNote 13(1,021,949)-Repayment of rolng-term debt(194,126)(34,59)Interest paid(500,000)Repayment of related party loan(500,000)Cash, beginning of period\$6,332,226\$(3,306,25)Cash, end of period\$12,341,673\$6342,20Interest paid during the period884,295185,81-	Cash used in operating activities		\$ (11,043,075)	\$ (5,007,69
Purchase of property, plant and equipmentNote 8(1,052,332)(1,548,92)Proceeds from disposal of property plant and equipment-706,93Investment in MMGC-(1,168,85)Payment of deposits and retainers(1,268,039)-Purchases of intangible assetsPayment of accrued transaction costs(38,413)-Net cash outflow on acquisition of subsidiaries-(21,750,00)Cash used in investment activities\$(2,358,784)\$INANCING ACTIVITIES(603,00)Repayment of share issuance costsNote 13(1,021,949)-Repayment of nog-term debt(194,126)(34,59)Interest paid(500,00)Cash provided by financing activities\$19,734,085\$25,819,37(500,00)Cash, beginning of period\$6,332,226\$(3,30,62,25)Cash, end of period\$12,341,673\$634,200Interest paid during the period884,295185,81-	NVESTING ACTITIVES			
Proceeds from disposal of property plant and equipment-706,93Investment in MMGC-(1,168,85Payment of deposits and retainers(1,268,039)-Purchases of intangible assetsPayment of accrued transaction costs(38,413)-Net cash outflow on acquisition of subsidiaries-(21,750,00Cash used in investment activities\$(2,358,784)\$TNANCING ACTIVITIES(603,00Issuance of common sharesNote 13(1,021,949)-Repayment of long-term debt(194,126)(34,59Interest paid-(500,00Cash provided by financing activities\$19,734,085\$Cash, beginning of period\$6,332,226\$(3,306,25Cash, end of period\$12,341,673\$634,20Interest paid during the period884,295185,81-	Deposits on property, plant and equipment	Note 8	-	(357,08
Investment in MMGC-(1,168,85Payment of deposits and retainers(1,268,039)-Purchases of intangible assetsPayment of accrued transaction costs(38,413)-Net cash outflow on acquisition of subsidiaries-(21,750,00Cash used in investment activities\$(2,358,784)\$TNANCING ACTIVITIES\$(2358,784)\$Issuance of common sharesNote 1321,669,00126,956,97Payment of share issuance costsNote 13(1,021,949)-Repayment of convertible notes-(603,00Repayment of long-term debt(194,126)(34,59Interest paid(718,841)-(500,00Cash provided by financing activities\$19,734,085\$Cash, beginning of period\$6,332,226\$(3,306,25Cash, end of period\$12,341,673\$634,20Interest paid during the period\$84,295185,81	Purchase of property, plant and equipment	Note 8	(1,052,332)	(1,548,92
Payment of deposits and retainers   (1,268,039)   -     Purchases of intangible assets   -   -     Payment of accrued transaction costs   (38,413)   -     Net cash outflow on acquisition of subsidiaries   -   (21,750,00     Cash used in investment activities   \$   (22,358,784)   \$   (24,117,93     TINANCING ACTIVITIES   -   -   (603,00   -   -   (603,00   -   -   (603,00   -   (194,126)   (34,59   -   (500,00   26,956,97   -   -   (500,00   -   -   (603,00   -   -   (603,00   -   -   (603,00   -   -   (500,00   -   -   (500,00   -   -   (500,00   -   -   (500,00   -   -   (500,00   -   -   (500,00   -   -   (500,00   -   -   (500,00   -   -   (500,00   -   -   (500,00   -   -   (500,00   -   -   (500,00   -   -   (500,00   -   -   (500,00   -   -   (500,00	Proceeds from disposal of property plant and equipment		-	706,93
Purchases of intangible assets-Payment of accrued transaction costs(38,413)Net cash outflow on acquisition of subsidiaries-Cash used in investment activities\$INANCING ACTIVITIESIssuance of common sharesNote 13Payment of share issuance costsNote 13Repayment of convertible notes-Repayment of long-term debt(194,126)Interest paid-Repayment of related party loan-Cash provided by financing activities\$19,734,085\$25,819,37And of period\$10,009,4473,940,46Cash, end of period884,295185,81	Investment in MMGC		-	(1,168,85
Payment of accrued transaction costs   (38,413)   -     Net cash outflow on acquisition of subsidiaries   -   (21,750,00     Cash used in investment activities   \$   (2,358,784)   \$   (24,117,93     FINANCING ACTIVITIES   -   (26,956,97   -   -   (603,00     Payment of share issuance costs   Note 13   (1,021,949)   -   -   (603,00     Repayment of convertible notes   -   -   (603,00   -   (500,00   -   (500,00   -   -	Payment of deposits and retainers		(1,268,039)	-
Net cash outflow on acquisition of subsidiaries     -     (21,750,00       Cash used in investment activities     \$     (2,358,784)     \$     (24,117,93       FINANCING ACTIVITIES     Issuance of common shares     Note 13     21,669,001     26,956,97       Payment of share issuance costs     Note 13     (1,021,949)     -     (603,00       Repayment of convertible notes     -     (603,00     (194,126)     (34,59       Interest paid     (718,841)     -     (500,00     -       Repayment of related party loan     -     (500,00     -     (500,00       Cash provided by financing activities     \$     19,734,085     \$     25,819,37       ncrease/(Decrease) in cash during the period     \$     6,332,226     \$     (3,306,25       Cash, end of period     \$     12,341,673     \$     634,20       nterest paid during the period     884,295     185,81	Purchases of intangible assets		-	-
Cash used in investment activities     \$ (2,358,784)     \$ (24,117,93       FINANCING ACTIVITIES     Issuance of common shares     Note 13     21,669,001     26,956,97       Payment of share issuance costs     Note 13     (1,021,949)     -       Repayment of convertible notes     -     (603,00       Repayment of long-term debt     (194,126)     (34,59       Interest paid     (718,841)     -       Repayment of related party loan     -     (500,00       Cash provided by financing activities     \$ 19,734,085     \$ 25,819,37       ncrease/(Decrease) in cash during the period     \$ 6,332,226     \$ (3,306,25       Cash, beginning of period     \$ 12,341,673     \$ 634,20       nterest paid during the period     884,295     185,81	Payment of accrued transaction costs		(38,413)	-
FINANCING ACTIVITIES     Note 13     21,669,001     26,956,97       Payment of share issuance costs     Note 13     (1,021,949)     -       Repayment of convertible notes     -     (603,00       Repayment of long-term debt     (194,126)     (34,59       Interest paid     (718,841)     -       Repayment of related party loan     -     (500,00       Cash provided by financing activities     \$ 19,734,085     \$ 25,819,37       ncrease/(Decrease) in cash during the period     \$ 6,332,226     \$ (3,306,25       Cash, beginning of period     \$ 12,341,673     \$ 634,20       nterest paid during the period     884,295     185,81	Net cash outflow on acquisition of subsidiaries		-	(21,750,00
Issuance of common shares     Note 13     21,669,001     26,956,97       Payment of share issuance costs     Note 13     (1,021,949)     -       Repayment of convertible notes     -     (603,00       Repayment of long-term debt     (194,126)     (34,59       Interest paid     (718,841)     -       Repayment of related party loan     -     (500,00       Cash provided by financing activities     \$     19,734,085     \$     25,819,37       ncrease/(Decrease) in cash during the period     \$     6,332,226     \$     (3,306,25       Cash, beginning of period     \$     12,341,673     \$     634,20       nterest paid during the period     884,295     185,81	Cash used in investment activities		\$ (2,358,784)	\$ (24,117,936
Payment of share issuance costs   Note 13   (1,021,949)   -     Repayment of convertible notes   -   (603,00     Repayment of long-term debt   (194,126)   (34,59     Interest paid   (718,841)   -     Repayment of related party loan   -   (500,00     Cash provided by financing activities   \$   19,734,085   \$   25,819,37     ncrease/(Decrease) in cash during the period   \$   6,332,226   \$   (3,306,25     Cash, beginning of period   \$   12,341,673   \$   634,20     Interest paid during the period   884,295   185,81	FINANCING ACTIVITIES			
Repayment of convertible notes   -   (603,00     Repayment of long-term debt   (194,126)   (34,59     Interest paid   (718,841)   -     Repayment of related party loan   (718,841)   -     Cash provided by financing activities   \$   19,734,085   \$   25,819,37     ncrease/(Decrease) in cash during the period   \$   6,332,226   \$   (3,306,25     Cash, beginning of period   \$   6,009,447   3,940,46     Cash, end of period   \$   12,341,673   \$   634,20     Interest paid during the period   884,295   185,81	Issuance of common shares	Note 13	21,669,001	26,956,97
Repayment of long-term debt   (194,126)   (34,59     Interest paid   (718,841)   -     Repayment of related party loan   -   (500,00     Cash provided by financing activities   \$ 19,734,085   \$ 25,819,37     ncrease/(Decrease) in cash during the period   \$ 6,332,226   \$ (3,306,25     Cash, beginning of period   \$ 12,341,673   \$ 634,20     Interest paid during the period   884,295   185,81	Payment of share issuance costs	Note 13	(1,021,949)	-
Interest paid     (718,841)     -       Repayment of related party loan     -     (500,00       Cash provided by financing activities     \$ 19,734,085     \$ 25,819,37       ncrease/(Decrease) in cash during the period     \$ 6,332,226     \$ (3,306,25       Cash, beginning of period     \$ 0,09,447     3,940,46       Cash, end of period     \$ 12,341,673     \$ 634,20       Interest paid during the period     884,295     185,81	Repayment of convertible notes		-	(603,00
Repayment of related party loan     -     (500,00       Cash provided by financing activities     \$     19,734,085     \$     25,819,37       ncrease/(Decrease) in cash during the period     \$     6,332,226     \$     (3,306,25       Cash, beginning of period     \$     0,009,447     3,940,46       Cash, end of period     \$     12,341,673     \$     634,20       Interest paid during the period     884,295     185,81	Repayment of long-term debt		(194,126)	(34,59
Cash provided by financing activities     \$ 19,734,085     \$ 25,819,37       ncrease/(Decrease) in cash during the period     \$ 6,332,226     \$ (3,306,25       Cash, beginning of period     \$ 6,009,447     3,940,46       Cash, end of period     \$ 12,341,673     \$ 634,20       nterest paid during the period     884,295     185,81	Interest paid		(718,841)	-
ncrease/(Decrease) in cash during the period     \$ 6,332,226     \$ (3,306,25     6,009,447     3,940,46       Cash, beginning of period     \$ 12,341,673     \$ 634,20     634,20     12,341,673      12,341,673 <th< td=""><td></td><td></td><td>-</td><td>(500,00</td></th<>			-	(500,00
Cash, beginning of period     6,009,447     3,940,46       Cash, end of period     \$ 12,341,673     \$ 634,20       Interest paid during the period     884,295     185,81	Cash provided by financing activities		\$ 19,734,085	\$ 25,819,37
Cash, end of period     \$ 12,341,673     \$ 634,20       Interest paid during the period     884,295     185,81	ncrease/(Decrease) in cash during the period		\$ 6,332,226	\$ (3,306,25
nterest paid during the period 884,295 185,81	Cash, beginning of period			 3,940,46
	Cash, end of period		\$ 12,341,673	\$ 634,20
	nterest paid during the period		884 295	185.81
	Taxes paid during the period		324,620	100,01

See accompanying notes to these consolidated financial statements

Notes to the Interim Condensed Consolidated Financial Statements (Expressed in U.S. dollars, unless otherwise stated) For the three and nine months ended September 30, 2018

#### 1. Incorporation and operations

Golden Leaf Holdings Ltd. ("Golden Leaf" or the "Company") is a publicly traded corporation, incorporated in Canada, operating primarily in the Oregon, Nevada, and Canadian markets. The company's shares are listed on the CSE under the trading symbol "GLH", as well as the OTCQB under the trading symbol "GLDFF".

The Company is in the business of producing and distributing cannabis oil and flower products within the Oregon and Nevada adult-use regulated markets as well as the Canadian medical market, primarily through its main operating subsidiaries, Greenpoint Oregon, Inc., Greenpoint Nevada, Inc., and CFA Retail, LLC, Medical Marijuana Group Corporation and Medical Marijuana Group Consulting Ltd. Starting in September 2018, the Company is also operating a dispensary in Northern California under a transitional consulting agreement.

#### 2. Going concern

Golden Leaf has been incurring operating losses and cash flow deficits since its inception, as it attempts to create an infrastructure to capitalize on the opportunity for value creation that is emerging from the gradual relaxing of prohibitions of cannabis in the United States on the cannabis industry. The Company's revenues have not yet risen to levels materially capable of covering the costs related to the infrastructure investment (both capital and operating). As such, the Company has been depleting its invested capital as it simultaneously navigates regulatory evolution and uncertainty, awaits the imminent changes in other jurisdictions that will fuel market expansion, and continues to make necessary investments.

As of September 30, 2018, the Company's cash balances were \$12,341,673. On January 31, 2018 the Company received gross proceeds of C\$17,554,050 from a bought deal private placement transaction, in addition to significant warrant exercise activity which has further bolstered the Company's cash position.

Although the Company has been successful in raising funds to date, there can be no assurance that adequate or sufficient funding will be available in the future or available under terms acceptable to us or that the Company will be able to generate sufficient cash flow from operations.

These circumstances indicate the existence of material uncertainty that casts substantial doubt as to our ability to meet our business plan and our obligations as they come due, and accordingly the appropriateness of the use of the accounting principles applicable to a going concern. The accompanying consolidated financial statements have been prepared on a going concern basis that assumes we will be able to continue to realize our assets and discharge our liabilities in the normal course of business, and do not reflect the adjustments to assets and liabilities that would be necessary if we were unable to obtain adequate financing. Such adjustments could be material. If we are unable to raise funds and execute our business plan, we may not be able to continue as a going concern.

#### 3. Statement of compliance

These interim condensed consolidated financial statements for the three and nine-month periods ended September 30, 2018 have been prepared in accordance with International Accounting Standard ("IAS") 34, 'Interim Financial Reporting' and in accordance with the accounting policies adopted in the Company's most recent annual financial statements for the year ended December 31, 2017. The interim condensed consolidated financial statements should be read in conjunction with the December 31, 2017 financial statements, which have been prepared in accordance with International Financial Reporting Standards ("IFRS").

Notes to the Interim Condensed Consolidated Financial Statements (Expressed in U.S. dollars, unless otherwise stated) For the three and nine months ended September 30, 2018

### 4. Basis of presentation

Except where specified, the consolidated financial statements have been prepared in U.S. dollars, which is the Company's presentation currency, on a historical cost basis except for biological assets, certain financial assets, and financial liabilities measured at fair value. The accounting policies set out below have been applied to all accounting periods. Certain prior period amounts have been reclassified for consistency with current period presentation. These reclassifications had no effect on the reported results of operations.

### 5. Significant accounting policies

The accounting policies applied in these interim condensed consolidated financial statements are the same as those applied in the Company's Consolidated Financial Statements for the year ended December 31, 2017 with the exception of the following:

#### Changes in Accounting Policies - Financial Instruments

The Company adopted all of the requirements of IFRS 9 Financial Instruments ("IFRS 9") as of January 1, 2018. IFRS 9 replaces IAS 39 Financial Instruments: Recognition and Measurement ("IAS 39"). IFRS 9 utilizes a revised model for recognition and measurement of financial instruments and a single, forward-looking "expected loss" impairment model. Most of the requirements in IAS 39 for classification and measurement of financial liabilities were carried forward in IFRS 9, so the Company's accounting policy with respect to financial liabilities is unchanged. As a result of the adoption of IFRS 9, management has changed its accounting policy for financial assets retrospectively, for assets that continued to be recognized at the date of initial application. The change did not impact the carrying value of any financial assets or financial liabilities on the transition date.

The following is the Company's new accounting policy for financial instruments under IFRS 9:

#### (i) Classification

The Company classifies its financial instruments in the following categories: at fair value through profit and loss ("FVTPL"), at fair value through other comprehensive income (loss) ("FVTOCI") or at amortized cost. The Company determines the classification of financial assets at initial recognition. The classification of debt instruments is driven by the Company's business model for managing the financial assets and their contractual cash flow characteristics. Equity instruments that are held for trading are classified as FVTPL. For other equity instruments, on the day of acquisition the Company can make an irrevocable election (on an instrument-by-instrument basis) to designate them as at FVTOCI. Financial liabilities are measured at amortized cost, unless they are required to be measured at FVTPL (such as instruments held for trading or derivatives) or if the Company has opted to measure them at FVTPL.

The Company completed a detailed assessment of its financial assets and liabilities as at January 1, 2018. The following table shows the original classification under IAS 39 and the new classification under IFRS 9:

Financial asset / liabilities	Original classification IAS 39	New classification IFRS 9
Cash	Amortized cost	Amortized cost
Account receivable	Amortized cost	Amortized cost
Account payable and accrued liabilities	Amortized cost	Amortized cost
Interest payable	Amortized cost	Amortized cost
Long-term debt	Amortized cost	Amortized cost
Convertible debentures	FVTPL	FVTPL
Related party notes payable	Amortized cost	Amortized cost
Warrants liability	FVTPL	FVTPL
Derivative liability	FVTPL	FVTPL

Notes to the Interim Condensed Consolidated Financial Statements (Expressed in U.S. dollars, unless otherwise stated) For the three and nine months ended September 30, 2018

### 5. Significant accounting policies (continued)

The Company did not restate prior periods as it recognized the effects of retrospective application to shareholders' equity at the beginning of the 2018 annual reporting period, which also includes the date of initial application. The adoption of IFRS 9 resulted in no impact to the opening accumulated deficit nor to the opening balance of accumulated comprehensive income on January 1, 2018.

#### (ii) Measurement

<u>Financial assets and liabilities at amortized cost</u>. Financial assets and liabilities at amortized cost are initially recognized at fair value plus or minus transaction costs, respectively, and subsequently carried at amortized cost less any impairment.

<u>Financial assets and liabilities at FVTPL</u>. Financial assets and liabilities carried at FVTPL are initially recorded at fair value and transaction costs are expensed in the consolidated statements of net (loss) income. Realized and unrealized gains and losses arising from changes in the fair value of the financial assets and liabilities held at FVTPL are included in the consolidated statements of net (loss) income in the period in which they arise.

#### (iii) Impairment of financial assets at amortized cost

The Company recognizes a loss allowance for expected credit losses on financial assets that are measured at amortized cost. At each reporting date, the Company measures the loss allowance for the financial asset at an amount equal to the lifetime expected credit losses if the credit risk on the financial asset has increased significantly since initial recognition. If at the reporting date, the financial asset has not increased significantly since initial recognition, the Company measures the loss allowance for the financial asset at an amount equal to the twelve month expected credit losses. The Company shall recognize in the consolidated statements of net (loss) income, as an impairment gain or loss, the amount of expected credit losses (or reversal) that is required to adjust the loss allowance at the reporting date to the amount that is required to be recognized.

#### (iv) Derecognition

<u>Financial assets</u>. The Company derecognizes financial assets only when the contractual rights to cash flows from the financial assets expire, or when it transfers the financial assets and substantially all of the associated risks and rewards of ownership to another entity. Gains and losses on derecognition are generally recognized in the consolidated statements of net (loss) income.

#### Changes in Accounting Policies - Revenue from Contracts with Customers

The company adopted all requirements of IFRS 15 Revenue from Contracts with Customers ("IFRS 15") as of January 1, 2018. IFRS 15 utilizes a methodical framework for entities to follow to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The change did not impact the cumulated revenue recognized or the related assets and liabilities on the transition date.

The company has assessed the impact from this new standard. Under IFRS 15, revenue from the sale of cannabis would be recognized at the point in time when control over goods has been transferred to the customer. The Company transfers control and satisfies its performance obligation upon delivery and acceptance by the customer, which is consistent with the Company's previous revenue recognition policy under IAS 18.

Based on the Company's assessment, the adoption of this new standard does not have a material impact on its consolidated financial statements.

Notes to the Interim Condensed Consolidated Financial Statements (Expressed in U.S. dollars, unless otherwise stated) For the three and nine months ended September 30, 2018

### 5. Significant accounting policies (continued)

#### New Accounting Policy – Biological Assets

On April 1, 2018, the Company adopted a production costs capitalization policy using an approach similar to the capitalization criteria outlined in IAS 2 *Inventories*. A portion of production costs related to the transformation of biological assets from the point of recognition to the point of harvest are capitalized and included in the fair value measurement of biological assets. Previously, production costs were expensed as incurred. The adoption of this policy does not represent a change in an accounting policy under IAS 8, *Accounting Policies, Changes in Accounting Estimates and Errors,* as production costs related to cannabis cultivation and grow activities were previously immaterial to the Company's financial results.

The new accounting policy and biological assets disclosure are consistent with the guidelines in Canadian Securities Administrators ("CSA") Staff Notice 51-357, *Staff Review of Reporting Issuers in the Cannabis Industry*.

#### 6. Accounts receivable

	Septe	ember 30, 2018	Decen	nber 31, 2017
Accounts receivable	\$	1,212,824	\$	377,746
Allow ance for doubtful accounts		(6,312)		-
	\$	1,206,512	\$	377,746

### 7. Biological assets and inventory

The Company's biological assets consist of cannabis plants that are cultivated at the Company's own grow facilities. Biological assets are valued in accordance with IAS 41 *Agriculture* and are presented at fair value less costs to sell up to the point of harvest, which becomes the basis for the cost of finished goods inventories after harvest. Since actively traded commodity market prices are not available for cannabis plants or dried product, the valuation of these biological assets is obtained using valuation techniques where the inputs are based upon unobservable market data (Level 3). Unrealized fair value changes on growth of biological assets are recorded in a separate line on the face of the statement of operations.

The valuation of biological assets is based on a market approach where fair value at the point of harvest is estimated based on the selling price less any costs to sell at harvest. For biological assets that are still growing, the fair value ascribed to them is a percentage of the fair value at point of harvest, based on where the plants are in their grow cycle. As at September 30, 2018, on average, the biological assets were 13% complete as to the next expected harvest date.

Production costs are marijuana cultivation costs including post-harvest costs and consist of labor, electricity, water, propane, testing fees, supplies, tools and materials, and depreciation of equipment and leasehold improvements and other related costs.

On April 1, 2018, the Company adopted a production costs capitalization policy using an approach similar to the capitalization criteria outlined in IAS 2 *Inventories*. A portion of production costs related to the transformation of biological assets from the point of recognition to the point of harvest are capitalized and included in the fair value measurement of biological assets. Previously, production costs were expensed as incurred. The adoption of this policy does not represent a change in an accounting

Notes to the Interim Condensed Consolidated Financial Statements (Expressed in U.S. dollars, unless otherwise stated) For the three and nine months ended September 30, 2018

### 7. Biological assets and inventory (continued)

policy under IAS 8, *Accounting Policies, Changes in Accounting Estimates and Errors*, as production costs related to cannabis cultivation and grow activities were previously immaterial to the Company's financial results.

In determining the fair value of biological assets, management is required to make several estimates with respect to significant unobservable inputs, including the expected yields for the cannabis plants, listed selling price of dry cannabis, the stage of plant growth at which point of harvest is determined, wastage and costs to sell. Estimated yield per plant varies by strain and is obtained through historical growing results or grower estimate if historical results are not available. The Company used a range of 90.8 to 177.66 grams per plant in the valuation of biological assets at September 30, 2018. The listed selling price of dry cannabis varies by strain and is obtained through listed selling prices or estimated selling prices if historical results are not available. The Company used a range of \$2.42 to \$4.19 per gram in valuation of biological assets at September 30, 2018. Fair value at the point of harvest is estimated based on the selling price less any costs to sell at harvest. For the nine months ended September 30, 2018, costs to sell were nil as the biological assets in Nevada and Canada were not sold to retail customers.

The following significant unobservable inputs, all of which are classified as level 3 on the fair value hierarchy, were key inputs used by management in determining the fair value of biological assets:

- Selling price per gram calculated as the weighted average selling price for all strains of cannabis sold by the Company, which is expected to approximate future selling prices. For the Company's Nevada cultivation, these prices were market prices as at September 2018. For the Company's Canadian cultivation, these prices represented the ultimate selling prices to wholesale buyers.
- Stage of growth represents the weighted average number of weeks out of the 16 week growing cycle that biological assets have reached as of the measurement date.
- Yield by plant represents the expected number of grams of finished cannabis inventory which are expected to be obtained from each harvested cannabis plant.
- Wastage represents the weighted average percentage of biological assets which are expected to fail to mature into cannabis plants that can be harvested.

The following table quantifies averages for each significant unobservable input, and also provides the impact a 10% increase/decrease in each input would have on the fair value of biological assets:

		10% c	hange as at
	September 30, Septe		tember 30,
	2018		2018
Selling price per gram	\$3.75	\$	20,000
Stage of grow th	2 w eeks	\$	1,000
Yield by plant	155.45 grams	\$	25,000
Wastage	5%	\$	1,000

The Company accretes fair value according to stage of growth. The plants in flowering cycle are ascribed higher value than plants in propagation and vegetative stages of growth as follows:

Notes to the Interim Condensed Consolidated Financial Statements (Expressed in U.S. dollars, unless otherwise stated) For the three and nine months ended September 30, 2018

Plant stage	Value ascribed	Stage of growth
Propagation	Nominal	2 - 4 weeks
Vegetative	25%	3 - 8 weeks
Flowering <50%	50%	8 - 12 weeks
Flowering >50%	100%	11 - ≥ 16 weeks

### 7. Biological assets and inventory (continued)

During the nine-month periods ended September 30, 2018 and 2017 the Company recognized \$247,715 and \$99,000, respectively, of gain on the change in fair market value of biological assets reflecting the increased value relating to the growth and harvest of the flower from cannabis plants.

This gain was calculated using a periodic change in value based on plant count and estimated value of the various products from the plants.

Inventory consists of cannabis flower, concentrated products such as oils and edibles, packaging, trim, and paraphernalia. Inventory costs are costs incurred to bring inventory to the condition and location of sale and include labor, packaging, transportation, depreciation of equipment, and other related costs.

During the nine-month periods ended September 30, 2018 and 2017, \$264,075 and \$106,038 respectively, of depreciation was allocated to inventory and expensed as cost of sales. Any costs

incurred to bring inventory to the condition and location of sale are included in cost. Inventory expensed to cost of sales for the nine-month periods ended September 30, 2018 and 2017 was \$9,579,838 and \$5,684,389, respectively. The following provides a summary of the various costs incurred in key stages of production:

ork-in-process iished goods	Biolo	Biological assets					
Raw materials	\$	-	\$	451,767			
Work-in-process		90,627		1,274,542			
Finished goods		-		1,896,946			
Balance, December 31, 2017	\$	90,627	\$	3,623,255			
Raw materials		-		1,305,616			
Work-in-process		218,060		1,025,382			
Finished goods		-		870,891			
Balance, September 30, 2018	\$	218,060	\$	3,201,889			

During the nine-month period ended September 30, 2018, the Company expensed \$192,100 of packaging materials to cost of sales which were destroyed due to obsolescence after the balance sheet date. The Company also recorded a general reserve for excess and obsolete inventory in the amount of \$192,100.

The Company's biological assets at September 30, 2018 is comprised of:

Balance, January 1, 2018	\$ 90,627
Gain on fair value of biological assets	247,715
Increase in biological assets due to capitalized costs	49,980
Transfer to finished goods	(170,262)
Balance, September 30, 2018	\$ 218,060

Notes to the Interim Condensed Consolidated Financial Statements (Expressed in U.S. dollars, unless otherwise stated) For the three and nine months ended September 30, 2018

### 8. Property, plant and equipment

		ildings and provements	L	and	Production equipment		asehold ovements	Computer Equipment	Fu	rniture and Fixtures	V	ehicles	Т	Total
Cost														
Balance, Jan 1, 2018	\$	867,351	\$29	0,404	\$1,835,863	\$3,	,736,610	\$ 235,778	\$	938,496	\$	222,112	\$ 8,	126,614
Additions		119,592		-	268,373		767,265	117,498		38,673		-	1,:	311,401
Dispositions		-		-	-		-	-		(36,236)		-	<b>7</b>	(36,236)
Balance, Sep 30, 2018	\$	986,943	\$29	0,404	\$2,104,236	\$4,	,503,875	\$ 353,276	\$	940,933	\$	222,112	\$ 9,4	401,779
Accumulated Amortiza	tion													
Balance, Jan 1, 2018	\$	-	\$	-	\$ (609,494)	\$ (	(920,057)	\$(109,279	) \$	(423,093)	\$	(107,781)	\$(2,	169,704)
Expense		(147,134)		-	(289,049)	(	(462,170)	(44,439	)	(144,423)		(36,823)	(1,	124,038)
Dispositions		-		-	-		-	-		36,236		-		36,236
Balance, Sep 30, 2018	\$	(147,134)	\$	-	\$ (898,543)	\$ (1,	,382,227)	\$ (153,718	) \$	(531,280)	\$	(144,604)	\$(3,2	257,506)
Carrying amount														
Balance, Jan 1, 2018	\$	867,351	\$29	0,404	\$1,226,369	\$2,	,816,553	\$ 126,499	\$	515,403	\$	114,331	\$ 5,9	956,910
Balance, Sep 30, 2018	\$	839,809	\$29	0,404	\$1,205,693	\$3,	,121,648	\$ 199,558	\$	409,653	\$	77,508	\$6,	144,273

Total depreciation expense for the nine months ended September 30, 2018 and 2017 was \$1,124,044 and \$331,960, respectively.

#### 9. Intangible Assets

	 Balance at nuary 1, 2018	А	dditions	•	oosals / stments	-	Balance at ep 30, 2018
Cost							
License	\$ 11,414,220	\$	-	\$	-	\$	11,414,220
Customer Relationships	1,512,896		-		-		1,512,896
Brands	13,300,000		-		-		13,300,000
Total	\$ 26,227,116	\$	-	\$	-	\$	26,227,116
Accumulated Amortization							
License	\$ -	\$	-	\$	-	\$	-
Customer Relationships	-		(220,803)		-		(220,803)
Brands	-		-		-		-
Total	\$ -	\$	(220,803)	\$	-	\$	(220,803)
Net book value	\$ 26,227,116	\$	(220,803)	\$	-	\$	26,006,313

### 10. Convertible debt and notes payable

	Septe	ember 30, 2018	Dece	ember 31, 2017
Current portion of convertible debentures carried at fair value	\$	-	\$	271,245
Mortgage note payable		313,815		389,916
Convertible debentures carried at fair value		11,645,447		30,360,225
Carrying amount of convertible notes at end of period	\$	11,959,262	\$	31,021,386

The Company has elected to account for the convertible debentures at fair value through profit and loss on initial recognition and as of the date of extinguishment for its convertible debentures. A gain of \$10,477,289 has been recorded through change in fair value of liabilities on the Interim Condensed Consolidated Statement of Operations and Comprehensive Gain (Loss) (Unaudited) for the nine-month period ended September 30, 2018.

For the year ended December 31, 2017, \$18.14 million debentures were converted. For the nine-month period ended September 30, 2018, \$7.05 million debentures have been converted.

Notes to the Interim Condensed Consolidated Financial Statements (Expressed in U.S. dollars, unless otherwise stated) For the three and nine months ended September 30, 2018

#### 11. Long-term debt

	Septemb	er 30, 2018	Dece	ember 31, 2017
Long term debt	\$	93,966	\$	211,991
Less: current portion		(29,511)		(131,610)
Carrying amount of long-term debt	\$	64,455	\$	80,381

Long term debt consists of vehicle loans, one of which was paid off in entirety in the second quarter of 2018. Vehicle loans of \$159,599 are secured by the Company's vehicles, due in June 2021 and repayable in monthly blended installments of \$2,155.

### 12. Warrants liability

	Units	Amount
Balance, December 31, 2017	117,765,944 \$	14,300,616
Warrants issued	38,980,000 \$	3,810,975
Warrants exercised	(18,481,615)	(3,077,592)
Change in fair market value		(9,254,878)
Balance, September 30, 2018	138,264,329 \$	5,779,121

In conjunction with the Company's bought deal unit financing which closed in January 2018, the Company issued 38,980,000 warrants exercisable for 24 months from the date of closing at a price of C\$0.55.

Per IFRS 9, certain warrants meet the definition of a derivative and must be measured at fair value at each reporting date. The warrants were valued at \$ 5,779,121 at September 30, 2018 and \$14,300,616 at December 31, 2017. For the nine months ended September 30, 2018, a gain of \$9,254,878 was recorded in the statement of operations due to significant changes in the market price of the common shares. The Black-Scholes option pricing model was used at the date of measurement with the following assumptions:

	September 30, 2018	December, 31 2017
Expected life	0.8 - 1.4 years	1.3 - 1.9 years
Risk-free interest rate	2.18%	0.84%
Dividend yield	0.00%	0.00%
Foreign exchange rate	0.7755	0.7701
Expected volatility	70.00%	70.00%

Volatility was calculated by using the historical volatility of other companies that the Company considers comparable that have trading and volatility history prior to the Company becoming public. The expected life in years represents the period that the warrants granted are expected to be outstanding. The risk-free rate is based on zero coupon Canada government bonds with a remaining term equal to the expected life of the options.

Notes to the Interim Condensed Consolidated Financial Statements (Expressed in U.S. dollars, unless otherwise stated) For the three and nine months ended September 30, 2018

### 13. Share capital

Share capital consists of one class of fully paid Ordinary Shares, with no par value. The Company is authorized to issue an unlimited number of Ordinary Shares. All shares are equally eligible to receive dividends and repayment of capital and represent one vote at the Company's shareholders' meetings.

The following table reflects the continuity of share capital from December 31, 2017 to September 30, 2018:

	Number of Shares	 Amount
Balance, December 31, 2017	477,000,336	\$ 108,552,681
Shares issued - conversion of debentures (i)	34,390,717	8,006,927
Shares issued - w arrant exercises (ii)	30,098,819	12,416,403
Shares issued - private placement financing (iii)	38,980,000	9,028,092
Shares issued - payment of accrued commissions and transaction costs (iv)	1,622,692	135,369
Shares issued - compensation options exercise (v)	500,000	109,928
Balance, September 30, 2018	582,592,564	\$ 138,249,400

- (i) During the first nine months of 2018, 33,590,465 shares were issued in respect of conversion of convertible debentures.
- (ii) The Company issued 30,598,819 shares upon exercise of warrants and compensation options.
- (iii) During the first nine months of 2018, 38,980,000 shares were issued in conjunction with the bought deal private placement unit offering resulting in gross proceeds of C\$17,541,000; C\$4,702,743 of these proceeds were allocated to warrant liabilities (Note 12). The Company paid share issuance costs of C\$1,263,779 for this transaction.
- (iv) The Company issued 1,622,692 shares as payment for accrued commissions payable and transaction costs.

#### 14. Warrant reserve

	Number of warrants issued	Exercise price	Amo	ount
Balance, December 31, 2018	29,274,531		\$	5,083,561
Warrants issued (i)	2,278,800	CDN \$0.45	\$	426,367
Warrants issued (ii)	5,425,995	CDN \$0.37		-
Exercise of compensation options (iii)	(10,851,990)		(	1,402,433)
Exercise of w arrants (iv)	(796,167)			(29,375)
Balance, September 30, 2018	25,331,169		\$	4,078,120

- (i) The Company issued 2,278,800 warrants as compensation options at C\$0.45 as part of the bought deal private placement offering.
- (ii) The Company issued 5,425,995 warrants at C\$0.37 upon exercise of compensation options. The value of these warrants has been previously recorded upon initial recognition of compensation options.
- (iii) During the first nine months of 2018, 10,851,990 compensation options were exercised.
- (iv) During the first nine months of 2018, 796,167 warrants were exercised.

Notes to the Interim Condensed Consolidated Financial Statements (Expressed in U.S. dollars, unless otherwise stated) For the three and nine months ended September 30, 2018

#### 14. Warrant reserve (continued)

The warrants were valued based on the fair value of services received unless the fair value of services received cannot be reliably measured, in which case the warrants are valued at fair value based on the Black-Scholes option pricing model at the date of measurement with the following assumptions:

	September 30, 2018	December, 31 2017
Expected life	0.8 - 1.4 years	1.3 - 1.9 years
Risk-free interest rate	2.18%	0.84%
Dividend yield	0.00%	0.00%
Foreign exchange rate	0.7755	0.7701
Expected volatility	70.00%	70.00%

Volatility was calculated by using the historical volatility of other companies that the Company considers comparable that have trading and volatility history prior to the Company becoming public. The expected life in years represents the period of time that the options granted are expected to be outstanding. The risk-free rate is based on zero coupon Canada government bonds with a remaining term equal to the expected life of the options.

### 15. Stock option plan

On January 1, 2015, the Company's Board of Directors approved a Directors, Management, Employees and Consultants Stock Option Plan to provide an incentive to its directors, executives and employees.

In accordance with terms of the employee share option plan, the exercise price of the granted options shall be determined at the time the option is granted provided that such price shall be not less than the market price of the Ordinary Shares. The total number of shares to be issued under the plan is not to exceed 10% of the total issued and outstanding shares. The options vest over 3 years with a one-year cliff and have an expiry period of no more than 10 years from the grant date.

Total number of options at December 31, 2017	22,	057,223
Options granted at \$0.46 Canadian dollars	2,	000,000
Options granted at \$0.39 Canadian dollars	24,	850,000
Options granted at \$0.30 Canadian dollars		200,000
Options granted at \$0.26 Canadian dollars	4,	250,000
Options granted at \$0.22 Canadian dollars	13,	750,000
Options exercised	(1	500,000)
Options expired	(12,	530,556)
Total number of options at September 30, 2018	54,	076,667
Number of exercisable options issued in Canadian dollars	22,	533,333
Number of exercisable options issued in U.S. dollars		508,333
Weighted average exercise price of options at September 30, 2018 in USD	\$	0.24

Notes to the Interim Condensed Consolidated Financial Statements (Expressed in U.S. dollars, unless otherwise stated) For the three and nine months ended September 30, 2018

### 15. Stock option plan (continued)

The options were valued based on the Black-Scholes option pricing model at the date of measurement with the following assumptions:

	September 30, 2018	December 31, 2017
Expected life	3 years	3 years
Risk-free interest rate	0.00% - 1.66%	0.00% - 1.59%
Dividend yield	0.00%	0.00%
Expected volatility	70.00%	70.00%
Expected forfeiture rate	0.00%	0.00%

During the nine months ended September 30, 2018 and 2017, \$2,183,179 and \$1,052,587, respectively, was included in stock compensation expense in the consolidated statement of operations.

On January 24, 2018, the Company issued 23,550,000 stock options to employees and consultants with an exercise price of C\$0.39.

On June 29, 2018, the Company issued 13,750,000 stock options to the Company's Board of Directors with an exercise price of C\$0.22.

### 16. Commitments

The Company and its subsidiaries have entered into operating lease agreements for the Company's dispensaries, corporate offices, wholesale warehouses, and grow facilities. Future lease payments amount to \$10,599,344:

2018	\$ 578,285
2019	2,620,634
2020	2,374,053
2021	1,980,889
2022	1,404,298
Thereafter	1,641,185
	\$ 10,599,344

### 17. Related party transactions

Key management of the Company are its Board of Directors and certain members of executive management. Key management personnel remuneration for the nine months ended September 30, 2018 and 2017 includes the following expenses:

	Septe	mber 30	),
	2018		2017
Salaries, commissions, bonuses and benefits	\$ 820,009	\$	586,707
Stock compensation, including warrants and shares, for officers and directors	932,245		660,896
	\$ 1,752,254	\$	1,247,603

The Company leases both its corporate headquarters in Beaverton, Oregon and its grow facility outside of Portland, which is currently under construction, from CPP OR LLC ("CPP"), of which Gary Zipfel, Director, is the sole member. To support the Company, CPP entered into a rent abatement agreement with the Company for the entirety of 2018 for its corporate headquarters and Oregon cultivation facility. Additional monthly rent in the amount of \$23,536 payable to CPP began in May 2018 to support the Company's

Notes to the Interim Condensed Consolidated Financial Statements (Expressed in U.S. dollars, unless otherwise stated) For the three and nine months ended September 30, 2018

### 17. Related party transactions (continued)

corporate headquarters and production build out costs and is included in its commitments schedule. Rent payment on the corporate headquarters and cultivation facility will resume in 2019.

#### 18. Capital management

The Company defines capital that it manages as its shareholders' equity, long-term debt, convertible debt, and warrant liability. The Company's objectives when managing capital are to safeguard the Company's ability to continue as a going concern in order to pursue the development of its business and to maintain a flexible capital structure that optimizes the costs of capital at an acceptable risk.

The Company manages and adjusts its capital structure based upon changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust the capital structure, the Company may issue shares, acquire debt, or acquire or dispose of assets.

To facilitate the management of its capital requirements, the Company prepares annual expenditure budgets that are updated as necessary depending on various factors, including successful capital deployment and general industry conditions. These budgets are approved by the Company's Board of Directors.

#### 19. Legal Matters

The Company and its wholly-owned subsidiary Greenpoint Real Estate, LLC ("GRE"), an Oregon limited liability company (collectively, the "Defendants"), were sued in the Circuit Court of the State of Oregon in Lane County on November 7, 2017 by the plaintiff, 3590 West 3rd Owner, LLC, an Oregon limited liability company ("Plaintiff"). The claims made by Plaintiff arise out of a lease between the parties and are breach of contract, foreclosure of landlord's lien and foreclosure of security interest. The amount of damages claimed are \$1,052,403, plus interest and certain other fees and costs. The Defendants deny all of the claims made and are preparing an Answer to file in response to the Plaintiff's Complaint against the Defendant's. The parties participated in a judicial settlement conference for Wednesday, March 14, 2018 in Portland, Oregon, for the purpose of attempting to reach a mutually agreeable settlement to resolve this matter. This attempt to settle was unsuccessful and on April 17, 2018 the Plaintiffs filed an Amended Complaint revising their prayed for damage amount from \$1,052,403 USD to \$3,210,328 USD. On May 1, 2018, the Defendant's \$42,931 counterclaim.

On August 31, 2018, Alex Wall and GRE (collectively, the "Plaintiffs"), filed a Complaint (the "Complaint") and Motion for Temporary Restraining Order ("TRO") against Daniel Berge (the "Defendant") in the Circuit Court for the State of Oregon in Clackamas County, Oregon. Plaintiffs' Complaint, alleges, among other claims, breach of contract and intentional interference with economic relations. The dispute essentially involves Plaintiffs' lease rights to a portion of certain real property located at 19630 S. McCord Road, Oregon City, Oregon (the "Premises"). Defendant had threatened to disregard Plaintiffs' lease rights and take other actions which would have interfered with Plaintiffs' rights to possession of the Premises and the GRE business activities being conducted there.

The Motion for TRO was granted and issued by the Circuit Court Judge on August 31, 2018.

On September 7, GRE and the Defendant entered into a Stipulated Preliminary Injunction, restraining the Defendant from:

a. Interfering with Plaintiff Alex Wall and GRE's right to possession of the Premises.

Notes to the Interim Condensed Consolidated Financial Statements (Expressed in U.S. dollars, unless otherwise stated) For the three and nine months ended September 30, 2018

#### 19. Legal Matters (continued)

- b. Interfering with the utilities provided to the Premises;
- c. Restricting Plaintiffs' access to the Premises, including restricting Plaintiffs' ability to ingress to and egress from the Premises from a certain driveway;
- d. Damaging the cannabis plants located in the Premises; and
- e. Removing any property from the Premises.

As part of the Stipulated Preliminary Injunction, Plaintiffs agreed to comply with State of Oregon medical marijuana laws at all times that Plaintiffs occupy the Premises with respect to their activities at the Premises.

There is no trial date set at this time for a hearing on the Plaintiffs' underlying Complaint and the Company and GRE are confident that these issues will be resolved without the need to go to trial. The Company assesses the likelihood of a potential lawsuit as neither remote nor probable, and therefore has not recorded a provision for this loss at September 30, 2018.

#### 20. Financial instruments and risk management

The Company, as part of its operations, carries several financial instruments. It is management's opinion that the Company is not exposed to significant interest, currency, credit, liquidity or other price risks arising from these financial instruments except as otherwise disclosed.

(a) Fair value

The carrying amounts of cash, accounts receivable, accounts payable, and accrued liabilities approximate their fair values because of the short-term maturities of these financial instruments.

The carrying value of long-term debt approximates fair value upon initial recognition. At September 30, 2018, its carrying value approximates fair value based on current market rates for similar instruments.

The following classifies financial assets and liabilities that are recognized on the balance sheet at fair value in a hierarchy that is based on significance of the inputs used in making the measurements. The levels in the hierarchy are as follows:

Notes to the Interim Condensed Consolidated Financial Statements (Expressed in U.S. dollars, unless otherwise stated) For the three and nine months ended September 30, 2018

#### 20. Financial instruments and risk management (continued)

Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities

Level 2 – Inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly or indirectly

	Category	Le	vel 1	Le	vel 2	Level 3	Total		
September 30, 2018			\$		\$	\$		\$	
Financial Assets									
Available for sale purchase option	FVTPL	\$	-	\$	-	\$ -	\$	-	
Financial Liabilities									
Warrant liability	FVTPL		-		-	5,779,121	5,779,121		
Convertible debentures	FVTPL		-		-	11,645,447		11,645,447	
							Total		
	Category	Le	vel 1	Le	vel 2	Level 3		Total	
December 31, 2017	Category	Le	vel 1 \$	Le	vel 2 \$	Level 3 \$		Total \$	
December 31, 2017 Financial Assets	Category	Le		Le	vel 2 \$				
· · · ·	Category FVTPL	Le \$		Le \$	vel 2 \$ _	\$ 	\$		
Financial Assets			\$		vel 2 \$ -	\$ 	\$		
Financial Assets Available for sale purchase option			\$		vel 2 \$ -	\$ 	\$		

Level 3 – Inputs for the asset or liability that are not based on observable market data.

The Company's finance team performs valuations of financial items for financial reporting, including Level 3 fair values, in consultation with third party valuation specialists for complex valuations. Valuation techniques are selected based on the characteristics of each instrument, with the overall objective of maximizing the use of market-based information.

The convertible debentures were valued using a binominal option pricing model to estimate the value of the combined convertible instrument. The most significant assumption used in this valuation is the expected volatility of the Company's shares which has been estimated at 70%.

Refer to Note 12 for further information on valuation of warrant liability.

The Company's risk exposures and the impact on the Company's financial instruments are summarized below:

(b) Credit risk

The carrying amounts of cash and accounts receivable on the consolidated statement of financial position represent the Company's maximum credit exposure at September 30, 2018.

The Company's principal financial assets are cash held at a highly rated financial institution and accounts receivable, which are subject to credit risk.

The Company's credit risk is primarily attributable to its accounts receivable. The amounts disclosed in the consolidated statement of financial position are net of allowance for doubtful accounts, estimated by the management of the Company based on its assessment of the current economic environment.

The Company does not have significant exposure to any individual customer and has bad debts of \$780 and \$141,325 for the three- and nine- months ended September 30, 2018, and allowance for doubtful accounts of \$6,312 at September 30, 2018 and \$0 at December 31, 2017. Doubtful accounts receivable of \$135,013 were written off as at September 30, 2018.

Notes to the Interim Condensed Consolidated Financial Statements (Expressed in U.S. dollars, unless otherwise stated) For the three and nine months ended September 30, 2018

#### 20. Financial instruments and risk management (continued)

#### (c) Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is not subject to any interest rate volatility as its long-term debt instruments and convertible notes are carried at fixed interest rates throughout their terms.

#### (d) Liquidity risk

The Company's objective is to have sufficient liquidity to meet its liabilities when due. The Company monitors its cash balances and cash flows generated from operations to meet its requirements. To ensure the Company has sufficient liquidity to meet its obligations, the Company intends to issue common shares and debt in the future. The following table summarizes the Company's contractual maturity for its financial liabilities, including both principal and interest payments:

		Carrying amount	-	ontractual ash flow s	Under 1 year			1-3 years	3-5	years	More tha 5 years	
As at September 30, 2018												
Trade and other payables	\$	2,341,474	\$	2,341,474	\$	2,341,474	\$	-	\$	-	\$	-
Loans and other borrowings		407,781		407,781		29,511		378,270		-		-
Convertible debt		11,645,447		11,645,447		-		11,645,447		-		-
Total	\$	14,394,702	\$	14,394,702	\$	2,370,985	\$	12,023,717	\$	-	\$	-

(e) Foreign exchange risk

Foreign currency exchange risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because they are denominated in currencies that differ from the respective functional currencies. The Company has financial assets and liabilities denominated in Canadian dollars. The Company does not hedge its exposure to fluctuations in foreign exchange rates.

The following is an analysis of U.S. dollar equivalent of financial assets and liabilities that are denominated in Canadian dollars at September 30, 2018:

Financial Assets	
Cash	\$ 5,070,033
Trade and other receivables	912,361
	\$ 5,982,394
Financial Liabilities	
Trade and other payables	\$ 628,720
Loans and other borrow ings	313,895
Convertible debt	11,645,447
	\$ 12,588,062

Notes to the Interim Condensed Consolidated Financial Statements (Expressed in U.S. dollars, unless otherwise stated) For the three and nine months ended September 30, 2018

### 21. Segmented Information

The Company defines its major operating segments as Oregon wholesale, Oregon retail, Nevada wholesale, Canada Cultivation and Canada Consulting. Due to the jurisdictional cannabis compliance issues ever-present in the industry, each state operation is by nature an operational segment. The Oregon wholesale and retail operations share supply chain components and cannot be discretely separated beyond gross margin; however, they have disparate revenue and margin metrics and thus will be presented as such. The Nevada wholesale operations are geographically and jurisdictionally distinct and are reviewed based on gross margin performance. The Canadian companies, although under common management, are different business models and thus are reviewed by management independently based on revenues and gross margin.

Key decision makers primarily review revenue, cost of sales expense and gross margin as the primary indicators of segment performance. The Oregon wholesale operation has historically been the major focus on the Company's management activities, however the addition of Retail and Nevada has further broadened the scope of management's activities. As these management activities continue to coalesce, the segment information will expand based on managements agreed upon allocation of costs beyond gross margin.

Liabilities

Notes to the Interim Condensed Consolidated Financial Statements (Expressed in U.S. dollars, unless otherwise stated) For the three and nine months ended September 30, 2018

	Oregon	n Retail	Oregon	Wholesale	Nevada	Nevada Wholesale			Canada Cultivation			Jons	sulting	Ot'	ther		Consolidated	
For the three months ended									-					 				
September 30,	2018	2017	2018	2017	2018	2017		2018	2017	7	2018		2017	2018		2017	2018	2017
Product sales	\$ 3,126,862	\$ 1,948,058	\$ 667,883	3 \$ 1,040,154	\$ 435,724	4 \$ 90,67	/9 \$	618,885	\$	- :	\$ 230,969	\$	-	\$ 23,928	\$	-	\$ 5,104,251	\$ 3,078,891
Royalties	-	-	-	-	-	-		-		-	-		-	-		50,000	-	50,000
Consulting revenue	-	-	-	-	-	-		-		-	8,662		-	-		-	8,662	-
Total Revenue	\$ 3,126,862	\$ 1,948,058	\$ 667,883	3 \$ 1,040,154	\$ 435,724	4 \$ 90,67	′9 \$	618,885	\$	- :	\$ 239,631	\$	-	\$ 23,928	\$	50,000	\$ 5,112,913	\$ 3,128,891
Inventory expensed to cost of sales	1,951,726	1,128,820	1,407,448	1,085,085	466,156	6 101,58	35	-		-	-		-	-		-	3,825,330	2,315,490
Production costs	-	-	135,428	180,581	-	- 63	32	341,084		-	-			 		-	476,512	181,213
Gross margin, excluding fair value items	\$ 1,175,136	\$ 819,238	\$ (874,993)	3) \$ (225,512)	\$ (30,432)	2) \$ (11,53	\$ (8ئ	277,801	\$	- '	\$ 239,631	\$	-	\$ 23,928	\$	50,000	\$ 811,071	\$ 632,188
Fair value changes in biological assets included																		
in inventory sold	-	-	-	-	(91,672)	2) -		-		-	-		-	-		-	- 91,672	-
(Gain) Loss on changes in fair value																		
of biological assets	-	-	-	-	24,640	) (99,00	JO)	433,902		-	-		-	-		-	458,542	(99,000)
Gross profit (loss)	\$ 1,175,136	\$ 819,238	\$ (874,993)	3) \$ (225,512)	\$ 36,600	) \$ 87,46	62 \$	(156,101)	\$	-	\$ 239,631	\$	-	\$ 23,928	\$	50,000	\$ 444,201	\$ 731,188

	Orego	n Retail	Oregon Wholesale		Nevada W	Vholesale	Canad	a Cultivation	Canada C	onsulting	Ot	her	Consolidated		
For the nine months ended	004.0	0017	0040	0017	0040	0047	0010	0047	0010	0047	0040	0047	0010	0047	
September 30,	2018	2017	2018	2017	2018	2017	2018	2017	2018	2017	2018	2017	2018	2017	
Product sales	\$ 7,705,954	\$ 2,915,738	\$ 1,688,395	\$ 4,420,961	\$ 1,184,161	\$ 90,679	\$ 618,88	5\$-	\$ 737,655	\$-	\$ 23,928	\$-	\$11,958,978	\$ 7,427,378	
Royalties	-	-	-	-	-	-	-	-	-	-	-	50,000	-	50,000	
Consulting revenue	-	-	-	-	-	-	-	-	35,838	-	-	-	35,838	-	
Total Revenue	\$ 7,705,954	\$ 2,915,738	\$ 1,688,395	\$ 4,420,961	\$ 1,184,161	\$ 90,679	\$ 618,88	5\$-	\$ 773,493	\$-	\$ 23,928	\$ 50,000	\$11,994,816	\$ 7,477,378	
Inventory expensed to cost of sales	5,164,680	1,529,039	3,561,847	4,053,765	852,920	101,585	391.0	0 -	-	-	-	-	9,579,838	5,684,389	
Production costs	-	-	367,888	519,646	14,366	632	505,48	5 -	-	-	-	-	887,739	520,278	
Gross margin, excluding fair value items	\$ 2,541,274	\$ 1,386,699	\$ (2,241,340)	\$ (152,450)	\$ 316,875	\$ (11,538	)\$113,00	9\$-	\$ 773,493	\$-	\$ 23,928	\$ 50,000	\$ 1,527,239	\$ 1,272,711	
Fair value changes in biological assets inclu	ded														
in inventory sold	-	-	-	-	37,976	-	-	-	-	-	-	-	37,976	-	
(Gain) Loss on changes in fair value															
of biological assets	-	-	-	-	(100,470)	(99,000	) (147,24	5) -	-	-	-	-	(247,715)	(99,000)	
Gross profit (loss)	\$ 2,541,274	\$ 1,386,699	\$ (2,241,340)	\$ (152,450)	\$ 379,369	\$ 87,462	\$ 260,25	4\$-	\$ 773,493	\$-	\$ 23,928	\$ 50,000	\$ 1,736,978	\$ 1,371,711	
	Oregon Retail Oregon Wholesale		Wholesale	Nevada V	Vholesale	Canad	Cultivation	Canada C	onsulting	0*	her	Consolidated			
	orego	in no tan	Gregori	molesale	No vaua v	molesale	Janau	Guillivation	Ganada G	onsunny	01		Colliso	induced	
A	sat Sep 30 2018	Dec 31 2017	Sep 30 2018	Dec 31 2017	Sep 30 2018	Dec 31 2017	Sep 30 201	8 Dec 31 2017	Sep 30 2018	Dec 31 2017	Sep 30 2018	Dec 31 2017	Sep 30 2018	Dec 31 2017	
Assets	\$41,081,471	\$ 3,540,876	\$12,216,379	\$ 9,800,715	\$ 4,549,132	\$ 3,389,811	\$ 11,864,39	7 \$ 1,336,736	\$ \$ 4,758,590	\$ 213,939	\$ 9,751,155	\$57,502,704	84,221,124	75,784,781	

\$ 331,191 \$ 221,724 \$ 6,928,411 \$ 516,381 \$ 259,663 \$ 113,243 \$ 296,466 \$ 399,517 \$ 163,827 \$ 206,801 \$ 21,813,793 \$ 56,580,980

29,793,351

58.038.646

Notes to the Interim Condensed Consolidated Financial Statements (Expressed in U.S. dollars, unless otherwise stated) For the three and nine months ended September 30, 2018

#### 22. Subsequent events

Subsequent to the balance sheet date, \$214,000 of debentures have been converted into 1,019,047 shares.

On November 5, 2018, the Company announced that it has signed a non-binding letter of intent to merge with Terra Tech Corp. ("Terra Tech"). The transaction is subject to several regulatory approvals, and the teams of both companies are collaborating in anticipation of joining forces.

On November 5, 2018, the Company announced launch of four flavours of Golden Fruit Chews in Nevada, complementing the Company's existing array of product offerings at the wholesale level.